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ABSTRACT
Cisplatin, despite being the cornerstone chemotherapy for the treatment of head and
neck squamous cell carcinoma (HNSCC), provides clinical benefits in just a subset of
patients. This together with the lack of biomarkers predicting therapeutic responses, have
led to unacceptably high rate of treatment failures in HNSCC. TP53 is the most frequently
mutated gene in HNSCC, and the effect of p53 loss or mutation on cisplatin responses in
HNSCC is poorly understood. In the current study, we hypothesized that HNSCC cells
respond to cisplatin in a p53 dependent manner and unambiguously show that presence of
wild-type TP53 (wtp53) confers sensitivity to cisplatin treatment in HNSCC cells, whereas
mutation or loss of TP53 imparts resistance to cisplatin treatment. Moreover, we report
that senescence, but not apoptosis is the prominent cellular response to cisplatin in wtp53
HNSCC cells and that the cisplatin resistance in p53-null or -mutant TP53 cells is due to
their inability to evoke senescence response. In an effort to find strategies of overcoming
cisplatin resistance in p53-deficient HNSCC cells, we found that a synthetic lethal strategy
through targeted inhibition of checkpoint kinases Chk1/2 leads to cisplatin sensitization of
v

p53-deficient cells through induction of mitotic death. Serendipitously, we also found out
that a significant subset (roughly 20%) of HNSCC cell lines are acutely sensitive to single
agent checkpoint inhibitors and that Chk1, but not Chk2, mediates this sensitivity.
Characterization of phenotypic and molecular responses to Chk1 inhibition in the Chk
sensitive and resistant cells revealed induction of early S phase arrest and DNA
damage/replication stress markers in the Chk sensitive, but not resistant cells. In addition,
we also found that inhibition of Chk1 kinase led to aberrant increase in origin of replication
firings in the sensitive, but not resistant cells and that loss of cdk2 or treatment with
Roscovitine rescues the lethal phenotype seen in the sensitive cells upon Chk1 inhibition.
These results suggest that exquisite sensitivity to Chk1 inhibition in a subset of HNSCC cells
could be due to these cells being in a pre-existing state of severe replication stress.
In summary, given the preponderance of p53 mutation in HNSCC and the widespread
use of cisplatin in treating aggressive HNSCC, we provide preclinical evidence that cisplatin
resistance of p53-deficient HNSCC cells can be overcome through inhibition of checkpoint
kinases 1/2. These preclinical data suggest that Chk1/2 kinase is a promising therapeutic
target in HNSCC and a precision approach using Chk inhibition in p53-mutant tumors may
be feasible for the treatment of HNSCC. We also show that targeted inhibition of Chk1
alone imparts lethality in a significant subset of HNSCC cells by inducing an aberrant
increase in origin firings. These results suggest that targeting Chk1 alone could be
therapeutically beneficial in a significant subset of HNSCC. Identifying those patients with
HNSCC that are particularly sensitive to Chk1 inhibition would enable more precise

vi

treatment selection thereby increasing the efficacy and decreasing the morbidity of
treatment of patients with this disease.
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CHAPTER 1: INTRODUCTION
1.1: Head and Neck Squamous Cell Carcinoma (HNSCC)
1.1.1: An Overview
Squamous cell carcinoma of the head and neck (HNSCC) consists of a group of
cancers that originate in the mucosal linings of upper aerodigestive tract and, in aggregate,
represent the sixth leading cause of cancer worldwide. It is expected that every year,
around 500,000 new cases of HNSCC will be diagnosed globally and roughly half this
number of patients will die of this disease each year [1-3]. HNSCC can arise at different
anatomical sites within the upper aerodigestive tract. The major sites of HNSCC origin are
the oral cavity, oropharynx, larynx or hypopharynx as shown in (Figure 1). In North
America, the most common form of HNSCC is the cancer originating in the oral cavity. The
different subsites within the oral cavity are shown in (Figure 2). Cancers originating at
these subsites have a spectrum of behavior and are treated differently [4].
As such HNSCC is regarded as a heterogeneous disease; however, a genetic
classification of this disease is still possible. Genetically, HNSCC could be broadly classified
into HPV positive and HPV negative HNSCC cancers. Moreover, HPV negative HNSCC that
constitute a majority of head and neck cancer can be further subdivided in two groups
based on the magnitude of gene copy number variations (CNVs), presence of p53 mutation
and ploidy status of the tumors as shown in (Figure 3) [1, 5-7].

1

Figure 1: HNSCC sites of origin
HNSCC is an epithelial malignancy of upper aero-digestive tract with diverse sites of origin.
The different anatomical sites of HNSCC are depicted in the image. Image taken from NCI
website (http://www.cancer.gov/cancertopics/factsheet/Sites-Types/head-and-neck) with
permission. For the National Cancer Institute © 2012 Terese Winslow LLC, U.S. Gov. has
certain rights.

2

Figure 2: Subsites of oral cavity
The different subsites within the oral cavity where HNSCC can arise are labeled in color.
Image taken from NCI website (http://www.cancer.gov/cancertopics/factsheet/SitesTypes/head-and-neck) with permission. For the National Cancer Institute © 2012 Terese
Winslow LLC, U.S. Gov. has certain rights.
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Figure 3: Genetic classification of HNSCC
HNSCC can be distinguished broadly into two subclasses based on the presence (HPV
positive) or absence (HPV negative) of high risk HPV 16,18 infection. Depending on the
magnitude of genetic alterations, the HPV negative HNSCCs can be further divided into two
categories: High chromosomal instability (High CIN) – HNSCCs containing numerous genetic
changes and Low chromosomal instability (Low CIN) – HNSCCs containing low number of
numerical genetic changes. The prevalence rates for each category are estimates only.
Image taken from Leemans, C.R., B.J. Braakhuis, and R.H. Brakenhoff, The molecular
biology of head and neck cancer. Nat Rev Cancer, 2011. 11(1): p. 9-22 with permission.
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1.1.2: Risk factors and prevalence
Tobacco use and alcohol consumption are the major risk factors associated with
HNSCC [8, 9]. Besides these, areca or betel nut chewing which is prevalent in South Asian
countries such as India, China, Taiwan, have also been implicated in the initiation of HNSCC
[10]. Over the past decade, due to decrease in the prevalence of smoking in the western
population, there has been a decline in the incidence of HNSCC at specific sites [1].
However, the cancers of oral tongue and, particularly, oropharynx are becoming more
prevalent. This may be related to the increased incidence of HPV infections in the oral and
oropharyngeal cancers. Besides the aforementioned risk factors, some inherited disorders,
such as Fanconi Anemia, Li Fraumeni and Bloom Syndromes are also known to predispose
to HNSCC [11-14].
1.1.3: HPV and HNSCC
The incidence of HPV-positive HNSCC has been increasing over the past decade. This
subclass of HNSCC commonly arises in the oropharynx and is linked with high risk HPV
infection [15-17]. HPV, which is a circular double-stranded DNA virus, has an affinity for
epithelium and is shown to be a primary cause of cervical cancer [1]. Over 100 subtypes of
HPVs have seen identified so far and of these, high risks HPV 16 and HPV 18, in particular,
are causally implicated in HNSCC [18-20]. Upon infecting the target cells, HPV16 transcribes
E6 and E7 oncoproteins which neutralize the function of wild-type p53 and Rb pocket
proteins, respectively, by causing their degradation [21]. As a result, HPV16/18 infected
cells escape p53 mediated death and enter cell cycle, thereby promoting viral duplication.
The HPV positive HNSCC are considered distinct entity from HPV-negative- HNSCC on
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account of the differences in the etiological factors, molecular expression profiles, and
clinical outcomes of these cancers [22-24]. In general, the HPV-positive HNSCC patients
tend to have more favorable prognoses as compared to non-HPV HNSCC patients [25, 26].
1.1.4: Pathogenesis of HNSCC and field cancerization
The understanding of the pathogenesis of squamous cell carcinoma has been
possible mainly due to the frequency of diagnosis of oral precursor lesions and the
availability of lesion specimens[1]. The most common precursor lesion in the mucosal
lining of the oral cavity is a white lesion called oral leukoplakia. However, not all oral
leukoplakia transform into oral cancer. At a prevalence rate of 0.1% to 0.5%, the
transformation rate of oral leukoplakia is assumed to be 1-2% annually [27, 28]. The
guiding risk factors for progression of precursor lesions are presence and grade of
dysplasia, female gender, and size of lesion [27]. Although chemopreventive treatment of
leukoplakia is considered appropriate and may be undertaken to cause its regression, a
lasting decrease in cancer incidence with this approach is rarely seen [29-31].
Field Cancerization
The term “field cancerization” was coined in 1953 to explain the propensity of local
recurrences and development of multiple primary tumors after treatment of head and
neck mucosa [1].

It was reported that the apparently normal mucosal epithelium

surrounding the squamous cell carcinoma are actually histologically dysplastic and they
contain genetic changes [32, 33]. These dysplastic epithelia surrounding the primary tumor
sites are considered the source for high incidence of local recurrences and multiple primary
tumors after treatment of HNSCC [33]. The existence of clonal relationship between the
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invasive carcinoma and the surrounding field led to the hypothesis that the tumor-adjacent
“field” of preneoplastic cells precede the development of invasive carcinoma[34].
However, the development of field is not considered first step towards progression into
invasive carcinoma. Focal patches of mucosal epithelium surrounding the primary tumor
were found to contain p53 mutations different from the primary tumor. This suggested
that the patches were not clonally related to the tumor [35]. These clonal units containing
p53 mutation are considered the first oncogenic changes in the mucosal epithelium. A
hypothetical model for HNSCC development using the patch–field–tumor–metastasis
progression has been proposed (Figure 4). Here, the mutation in p53 tumor patch is
considered as the first genetic change in the mucosa along with the appearance of
genetically defined field [1].
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Figure 4: Model of molecular carcinogenesis for HNSCC
The genetic events involved in the development of HNSCC are depicted in the figure. First,
a progenitor cell within the normal mucosa acquires one (or more) genetic alterations,
including a mutation in p53. Subsequent cell divisions give rise to a patch containing
daughter cells with mutation in p53, which can be detected through immunostaining. The
patch develops into an expanding field by breaking out of the normal growth control
and/or gaining growth advantage. The expanding field laterally replaces the normal
mucosal epithelium. A subclone of this field acquires further genetic alterations and
evolves into a tumor or invasive cancer. ↓ represents loss, ↓ ↓ represents homozygous
loss, ↑↑ represents high level amplification. Image taken from Leemans, C.R., B.J.
Braakhuis, and R.H. Brakenhoff, The molecular biology of head and neck cancer. Nat Rev
Cancer, 2011. 11(1): p. 9-22 with permission.
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1.1.5: Common genetic alterations in HNSCC
Studies investigating common genetic alterations in HNSCC had previously reported
mutations in a number of genes such as TP53, CDKN2A, PIK3CA, PTEN, and HRAS. In
addition, two independent groups in their recently performed study using whole exome
sequencing, identified genetic mutations in several other genes such as NOTCH1, FAT1,
CASP8, and FBXW7 [36, 37]. The mutational spectrum of HNSCC is shown in (Figure 5).
Among these genetic alterations, tumor suppressor gene TP53 is found to be mutated in
50-80 % of HNSCC patients, making it the most frequently mutated gene in head and neck
cancer. The second most frequently mutated gene is NOTCH1, followed by FAT1, CDKN2A,
PIK3CA, FBXW7, and HRAS.
Besides mutations, many copy number alterations in several genes are found in
HNSCC [20, 38-42]. For example, amplification of the EGF receptor (EGFR) that is known to
promote proliferation, is found in 10-30% of HNSCC patients[1]. Another common
alteration found in HNSCCs is disruption in retinoblastoma pathway (Rb pathway) which
occurs through amplification in cyclin D1, and/or deletions, mutation or methylation of
CDKN2A [41]. An integrated genomic analysis of HNSCC patient tumor specimens reported
focal deletions in chromosomal arms containing candidate tumor suppressors such as FHIT
and CSMD1 [41]. In addition, arm level gains on chromosomes containing candidate cancer
driver genes such as TP63, PIK3CA, TERC, PRKCI, and MYC were reported in the same study.
Many of these genetic alterations have been reported previously, however, the functional
consequences of many of these genetic alterations in HNSCC are yet to be worked out in
details.
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Figure 5: Frequent mutations in HNSCC
The figure above represents commonly found mutations in HNSCC. TP53 is the most
frequently mutated gene in HNSCC, followed by NOTCH1, CDKN2A, PIK3CA, FBXW7, and
HRAS. Image provided by Curtis R.Pickering.
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1.1.6: Treatment of HNSCC
Surgery, radiation and chemotherapy are the mainstay treatments for head and neck
cancer. The decision on the treatment of choice is taken after considering several factors.
These include tumor site, stage, functional outcomes and morbidities associated with
various approaches and patient related factors such as performance status, comorbidities
and preference (UptoDate.com). Patients with early stage disease are generally managed
with single modality treatment which is either surgery or radiation therapy, and those with
advanced stage are typically managed with multi-modality treatment that could include
organ preservation approaches with chemoradiotherapy (UptoDate.com). Cisplatin is the
chemotherapeutic agent of choice in the chemoradiotherapy regimen for treating
advanced HNSCC. Cetuximab, anti-EGFR antibody, is the only targeted therapy approved by
FDA in head and neck cancer. A combination regimen of radiotherapy and cetuximab is
often used for the treatment of selected patients [43]. Palliative chemotherapy and/or
supportive care are reserved for the patients with locally recurrent or metastatic disease.
HPV positive HNSCC patients are typically offered single modality radiotherapy or
chemoradiotherapy depending on the overall disease burden [44].

1.2: Cisplatin
1.2.1: A brief background
The biological activity of platinum compounds was discovered serendipitously during
an experiment that was designed to examine the effect of electric field on the growth of
Escherichia coli cells [45, 46]. Cis-diamminedichloroplatinum(II), or cisplatin, that became
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one of the successful platinum compounds was known since 1845 [46]. However, its
antitumor activity was not established until 1970. Cisplatin was approved by the FDA in
1978, and since then cisplatin has revolutionized therapeutic management of several types
of cancers such as those of the ovary, testes, and the head and neck [46, 47]. For testicular
cancer, if diagnosed early, the cure rates with cisplatin treatment are greater than 90% [46,
48]. In addition to the above malignancies, cisplatin now also forms a part of the treatment
regimens for mesothelioma, esophageal, stomach and prostate cancers, small and nonsmall cell lung, breast, cervical, Hodgkin’s and non-Hodgkin’s lymphomas, multiple
myeloma, neuroblastoma, sarcomas, and melanoma[46, 49].
1.2.2: Structure and Reactivity
Cisplatin, is a neutral, inorganic compound composed of heavy metal platinum ion at
the center and surrounded by two amine and two chloride groups in a square arrangement
as shown in (Figure 6) [47]. Once inside the cell, cisplatin is activated by a series of
aquation reactions in which the cis-chloro ligands are replaced by water molecules [50-52].
The aquated form is a high reactive species that can interact with intra-cellular targets.
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Figure 6: Cisplatin- Structure and intracellular activation
Intra-cellular entry of cisplatin triggers a hydrolysis reaction in which the two chloride
atoms are replaced with water molecules. As a result, cisplatin becomes highly reactive
towards intra-cellular targets.
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1.2.3: Mode of Action
It is widely recognized that the primary cellular target of cisplatin is DNA [47, 52].
Inside the cell, the reactive aquated form of cisplatin interacts with nucleophilic N7 sites of
the purine bases of the DNA to form DNA–protein and DNA–DNA interstrand and
intrastrand crosslinks [47]. The intrastrand DNA adducts contributes majorly to the
cisplatin induced cytotoxicity because intrastrand ApG and GpG crosslinks account for 85–
90% of total DNA lesions [53, 54]. Indeed, studies have reported that there exists a linear
correlation between the gross levels of platinum bound to DNA and the degree of
cytotoxicity[55]. A major consequence of cisplatin-DNA crosslinks is that it inhibits the vital
cellular processes of DNA synthesis and transcription. However, no correlation has been
found between these processes and cell death [47, 56, 57]. The other major cellular effects
of cisplatin-DNA adducts include induction of cell cycle checkpoints, activation of stress
pathways, and the therapeutically beneficial program of apoptosis [47]. Besides apoptosis,
platinum analogues have also been shown to elicit other cellular outcomes such as mitotic
catastrophe and senescence [58-60].
1.2.4: Modes of Cell Death
Apoptosis
Treatment with cisplatin may result in apoptosis or “programmed cell death” that is
characterized by unique morphological and biochemical features. These include cytoplasm
shrinkage, cellular blebbing, loss of cell-cell contact, chromatin condensation with
activation of endogenous endonucleases [58]. The process of apoptosis could be divided
into three stages. The first one is an initiation phase in which an external or internal
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apoptotic stimulus triggers activation of initiator caspases (caspases 2, 8 and 9). The next
one is an effector phase, in which initiator caspases cleave and activate effector caspases
(caspases 3, 6 and 7). The effector phase is also regulated by the relative levels of
proapoptotic (Bax, Bak, Bad) and antiapoptotic (Bcl-2, Bcl-xL, Mcl-1, Bcl-w and A1) families
of proteins [61]. Activated effector caspases, then initiate irreversible execution phase, in
which some proteins autodigest, and the cellular endonucleases begin to cleave the DNA
[58].
Senescence
Cell treated with cisplatin can enter a terminally irreversible non-proliferative state
called senescence that is characterized by large “pan cake” like cell morphology, and the
presence of the senescence-associated β-galactosidase (SA-β-gal) marker, which is
detected using X-gal as a substrate at pH 6.0 [62, 63]. A number of in-vitro studies have
highlighted the importance of intact p53-p21 pathway for the induction of the senescent
phenotype in cancer cells in response to various genotoxic therapies [64]. Contrary to
these results, some other studies have argued that cellular factors besides p53 and p21
may also lead to senescence induction [64, 65]. Whether induction of senescence in
response to treatment is therapeutically desirable is still an outstanding question. Although
senescent cells don’t divide, they are metabolically active. It has been shown that
senescent cells secrete factors that have growth promoting effect on the neighboring
tumor cells [66, 67].

Thus, it is conceivable that senescent cells may protect the

neighboring cells that have not undergone senescence in response to treatment [64].
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Mitotic Catastrophe
Mitotic catastrophe is a form of cell death that results due to faulty mitosis and is
characterized by the formation of large non-viable cells with several micronuclei [59, 64].
Cells undergoing mitotic catastrophe are morphologically distinguishable from apoptotic
cells. Although it is considered fundamentally different from apoptosis, several in-vitro and
in-vivo models have shown that mitotic catastrophe may share some characteristics of
apoptosis such as release of pro-apoptotic proteins and caspase activation [60]. Mitotic
catastrophe has been described as the principal mode of cell death in response to radiation
and also has been identified as prominent cellular response to various anti-tumor drugs
such as taxol, etoposide, cisplatin and bleomycin [64]. Abrogation of G1, G2 checkpoints or
deficiencies in spindle assembly proteins are known to stimulate induction of mitotic
catastrophe in cancer cells [60].
1.2.5: Modes of cisplatin resistance
Although cisplatin is an effective chemotherapeutic for the treatment of many
cancers, the therapeutic benefits offered by cisplatin may become limited due to problems
of therapy resistance. The resistance may be acquired through chronic exposure to the
drug or it may be an inherent cellular phenomenon. Several mechanisms of cisplatin
resistance have been described. These include decreased cellular uptake of the drug
and/or increased drug efflux, drug inactivation by increased levels of cellular thiols,
increased tolerance to drug induced DNA damage, enhanced nucleotide excision repair or
attenuated mismatch repair activity, and evasion of apoptosis [47, 52]. Several studies
investigating cisplatin resistance in tumor cells have encountered multiple mechanisms of
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resistance in the same tumor cells which suggests that cisplatin resistance could be
multifactorial [47, 68-71]. It has been reported that processes aiding reduced drug
accumulation in cancer cells contributes significantly to the mechanism of cisplatin
resistance [54]. Inhibition of drug uptake process is thought to be the prominent reason for
reduced drug accumulation. However, the mechanism of this process still remains obscure.
Reduced drug accumulation may also be an outcome of increase in drug efflux processes.
Indeed, overexpression of genes involved in drug efflux such as MRP2, ATP7A, ATP7B and
P-Glycoprotein pump have been found in cisplatin resistant cancer cells [72-77].
Resistance to cisplatin treatment can also develop due to elevation in the levels of
nucleophilic GSH (glutathione) or cysteine rich metallothionein. These two molecules
provide ideal reactive centers for cisplatin engagement and thus can lead to reduced
availability of cisplatin for interaction with its target DNA [54]. In addition, specific DNA
repair pathways may be induced by tumor cells in order to remove DNA lesions and
overcome cisplatin induced cytotoxicity. NER is the major pathway responsible for
removing platinum adducts and initiating repair of DNA lesions caused by cisplatin [78, 79].
Elevated levels of critical molecules in the NER pathway such as ERCC1 and XPA have been
reported in cisplatin resistant cancer cells, while cisplatin sensitive cells were shown to
express these proteins at low levels [80-83]. Cancer cells can also pose resistance to
cisplatin therapy by evading detection of DNA lesion caused by cisplatin. Mismatch repair
complex (MMR) which is mainly involved in DNA damage recognition process and also for
initiation of apoptotic pathway is a common target of alteration by cancer cells [47, 84].
Attenuation of MMR pathway through downregulation or mutation in critical MMR
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complex proteins such as hMSH1 and hMSH2, have been reported in cisplatin resistant
cancer cells [85-88]. Finally, tumor cells can circumvent the induction of apoptosis by
causing alteration in key genes in the apoptotic pathway and exhibit resistance to cisplatin.
Presence of wild-type (wt) p53 is known to be critical for the induction of apoptosis in
response to cisplatin treatment and tumor cells exhibiting defect in the apoptotic function
of p53 due to loss or mutation (mutp53), were found to be resistant to cisplatin [89-92].
However, resistance to cisplatin under wtp53 setting or sensitivity in a mutp53 background
has also been reported in some tumor models indicating that the role p53 in mediating
tumor response to cisplatin could be cell type dependent [93, 94]. Tumor cells can also
manifest apoptotic resistance to cisplatin through suppression of pro-apoptotic proteins
such as BAX, BAD and/or elevation in the expression levels of anti-apoptotic proteins such
BCL2, XIAP, or survivin [47, 95, 96].

1.3: DNA Damage Response (DDR)
1.3.1: DDR
Cells are endowed with a range of pathways to safeguard and preserve the genomic
integrity against endogenous and exogenous DNA insults. Upon encountering DNA
damage, cells initiate signaling cascades that form complex network and lead to an
appropriate cellular response. Depending on the type and extent of DNA damage, these
cellular responses may vary from transcriptional changes, cell cycle arrest to DNA repair
and induction of cell death. The entire cellular program activated upon DNA damage, from
damage recognition to regulation of cellular processes to cope with the damage, is termed
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as the DNA damage response [97]. Although we have obtained reasonable understanding
of the DDR pathways over the past decades, the complete picture of how cells protect and
preserve their genomic information is still unclear.
Owing to the complexity of the DDR pathway, only a brief overview of important
signaling pathways will be presented here. The proteins and pathways that are of
immediate relevance to the study will be introduced in detail. The phosphorylation events
form the heart of the DDR pathways. The proteins participating in the DDR pathway can be
grouped under three categories: sensors, mediator and effectors [97]. The sensors are
involved in the recognition of DNA lesions and are activated at the site of DNA damage.
Once activated, they pass on signals to the mediators which in turn activate effector
molecules that regulate and mount an appropriate response. It is worthwhile to note that
this functional differentiation by no means is absolute, as several proteins may have dual
roles and can function as sensors as well as mediators.
1.3.2: Sensors of DNA damage: ATR, ATM and DNA-PK
The most widely-recognized sensors of DNA damage are the members of
phosphatidylinositol 3-kinase-related kinase (PIKK) family, namely Ataxia-telangiectasia
mutated (ATM), ATM- and Rad3-related (ATR) and DNA-dependent protein kinase (DNAPK) [98]. These three kinases act on the same minimal substrate phosphorylation motif
that consists of serine/threonine followed by glutamine in the +1 position [99]. Upon
activation by the DNA damage, each of these kinases phosphorylate a multitude of
proteins [100]. Many of these target proteins can be phosphorylated by all three kinases
because of their shared substrate specificity. Nevertheless, a subgroup of targets is unique
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to each kinase. For this distinction, activation of separate response pathways is possible by
each of these kinases. The kind of DNA lesion guides the choice of DDR pathway but all
activated pathways evoke the same pattern of cellular responses [101]. The two most
common lesions generated upon exposure to genotoxic stresses are DSBs or SSBs. In
addition, exposure to replication stress inducing agents can lead to long stretches of ssDNA
due to polymerase-helicase uncoupling [102]. A simplified overview of kinase pathways
activated in DNA damage response is shown in (Figure 7).
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Figure 7: Kinase pathway activated in the DDR
DSBs lead to an activation of ATM and DNA-PK, while ATR is activated in response to SSBs
or upon generation of ssDNA. The activated kinases then phosphorylate hundreds of
proteins including Chk1 and Chk2 which relay the signals to downstream molecules. The
cellular processes affected due to the DDR signaling include transcription, cell cycle
checkpoints, DNA repair, and cell death.
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1.3.2.1: ATM/Chk2 pathway
The ATM/Chk2 pathway is mainly activated in response to radiation and other
genotoxins that induce DSBs [103]. The presence of DSBs trigger recruitment of ATM and
Mre11: Rad50: Nbs1 (MRN) sensor complex at the site of DNA damage where these two
molecules are activated in conjunction [104, 105]. The ATM activation is initiated by a
trans-autophosphorylation event on the ATM homo-dimers which causes their dissociation
[106]. Members of the MRN complex then interact with ATM and lead to its full activation.
After its activation, one of the key downstream substrates phosphorylated by ATM is Chk2,
a serine/threonine kinase. Activated Chk2 disperses throughout the nucleus and acts on
substrates involved in cell cycle control, transcription, apoptosis [107]. These include cdc25
family phosphatases, transcription factors p53, its regulator MDMX, BRCA1, FOXM1 and
E2F1 [107-110].

In addition, ATM also regulates the function of repair pathways,

Homologous Repair (HR) and Non-Homologous End Joining (NHEJ), at the site of DSBs
[111].
1.3.2.2: ATR/Chk1 pathway
The ATR-Chk1 pathway is mainly activated when cells are exposed to the agents that
induce SSBs or upon generation of ssDNA as result of polymerase-helicase uncoupling or
during DNA repair [99, 112]. Formation of ssDNA is a critical step for the activation of ATR.
Once the ssDNA is generated, Replication Protein A (RPA) recognizes and binds to ssDNA,
and interacts with ATR interacting protein (ATRIP), the binding partner of ATR. The
activation of ATR is then facilitated through the action of its binding partner ATRIP. The
efficient activation of ATR and its downstream substrate Chk1 is mediated by two proteins
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TopBP1 and Claspin. TopBP1 is recruited at the ssDNA-RPA site by PCNA-like Rad9: Rad1:
Hus1 checkpoint clamp. The TopBP1 recruitment leads to stimulation of ATR activity
through one of its domains, however, the steps involved remain unknown [113]. After its
activation, ATR phosphorylates claspin which is associated with active replication forks.
Phosphorylated claspin then binds and recruits Chk1 to the ssDNA-RPA complex, and brings
it to the close proximity of active ATR [114-116].
Activated ATR phosphorylates Chk1 at multiple sites within its C-terminal regulatory
domain, most notably at S317 and S345, thereby relieving the inhibitory action of this
domain. The two phosphorylation sites, particularly S345, are important for the biological
activity of Chk1 kinase. Chk1 kinase undergoes autophosphorylation at S296 during its
activation and this site is now commonly used as a read out for its activity. It is believed
that fully activated Chk1 dissociates from the chromatin and phosphorylates nuclear as
well as cytoplasmic substrates[107]. The canonical downstream substrates of Chk1 include
CDC25A and CDC25C phosphatases that are involved in cell cycle regulation [117].
Furthermore, Chk1 is known to modulate HR by catalyzing the phosphorylation of RAD51
and BRCA2 [118, 119]. Active Chk1 kinase is known to localize at centrosomes where it is
thought to control the onset of mitosis by regulating activation of mitotic cyclin B-CDK1
complex [120].
1.3.2.3: DNA-PK
Besides ATM, the DSBs also can result in an activation of DNA-PK. DNA-PK has far less
number of downstream substrates, and hence, it is thought to have less crucial function in
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DDR pathway as compared to ATR and ATM kinase. The most notable function of DNA-PK
seems to be in the stabilization of DNA ends during the repair of DSBs in NHEJ [111, 121].

1.4: Cell Cycle Regulation
The evolutionary conserved process of the cell cycle that regulates the cell division is
an important target of DDR pathway. The cell cycle consists of four sequential phases: G1S-G2-M. Progression of cell cycle through each of these four phases is mediated mainly
through the action of CDKs and their regulatory binding partners, cyclins [111]. Naturally,
the CDKs are the targets for modulation of the built-in sensor mechanisms whenever there
is a threat to the genome. These mechanisms are called checkpoints. The important
function of the checkpoints is to maintain the integrity of the genome and ensure orderly
completion of each cell cycle phase. A graphic representation of the cell cycle components
and checkpoints are shown in (Figure 8).
1.4.1: Cell Cycle Checkpoints
1.4.1.1: G1-S checkpoint
Detection of DNA damage in the G1 phase of the cell cycle triggers the G1-S
checkpoint which prevents the damaged cells from initiating DNA replication. P53 is the
master regulator of the G1-S checkpoint that can be activated directly or indirectly through
ATR-Chk1 or ATM-Chk2 pathways. Phosphorylation of p53 by these two pathways disrupts
it’s interaction with MDM2 and results in p53 stabilization and accumulation [122]. The
accumulated transcriptionally-active p53 induces p21 protein, which blocks the induction
of S phase through potent inhibition of CDK4 and CDK2. In addition, p53 also has an impact
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on the activity of Rb/E2F complex that are vital for the maintenance of the checkpoint.
Cancers in which the transcriptional function of p53 is lost due to mutation, deletion, or
viral oncoprotein mediated p53 degradation possess a defective G1-S checkpoint, and
hence are unable to arrest their cell cycle in G1 phase in response to DNA damage [101,
123, 124].
1.4.1.2: G2-M checkpoint
Incomplete DNA replication or DNA damage detection in the G2 phase triggers the
G2-M checkpoint which prevents the entry of the damaged cells into mitosis. The initiation
of mitotic entry occurs through the activation of mitotic cyclin B-CDK1 complex that causes
breakdown of nuclear envelope and start of prophase. Two parallel pathways function to
inhibit the activation of cyclin B-CDK1 complex: the Chk1/Chk2-CDC25 phosphatase
pathway and the Wee1-Cdk1 pathway. In the Chk1/Chk2-CDC25 phosphatase pathway,
Chk1/Chk2 kinases inactivate the phosphatases CDC25A and CDC25C that remove the
inhibitory phosphorylation Ty15/Thr14 on CDK1. The inactivation of CDC25A is
accomplished by phosphorylation on its S123 site by Chk1, which serves as a signal for
ubiquitin mediated proteosomal degradation [125]. On the other hand, CDC25C is
inactivated through cytoplasmic sequestration, which is induced due to Chk1
phosphorylation on its S216 site [126]. In contrast to the Chk1/Chk2-CDC25 pathway,
Wee1 kinase directly inhibits the activity of Cdk1 by adding the inhibitory phosphorylation
Ty15 and Thr14 on Cdk1. Activation of either of these pathways lead to cell cycle arrest in
the G2 phase. Recent studies have identified p38 kinase as a new inducer of G2-M
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checkpoint [127, 128]. Furthermore, it has been reported that transcriptional activities of
p53 and BRCA1 can also contribute towards sustaining the G2-M checkpoint arrest [123].
1.4.1.3: Intra-S-checkpoint
Inhibition of DNA synthesis triggers an intra-S-checkpoint which leads to stabilization
of stalled replication forks, suppression of latent origin firings and delay in the onset of
mitosis until genomic duplication is complete. The ATR-Chk1 pathway plays an important
role in all these responses [129, 130]. The critical target for modulation by the ATR-Chk1
pathway is CDK2, a key molecule involved in the S phase progression [123]. However,
recent studies have revealed that CDK1 can also compensate for the loss of CDK2,
suggesting that CDK1 and CDK2 may have redundant function in the S Phase [131, 132]. In
the S phase, CDKs contributes towards regulation of DNA synthesis primarily by controlling
the firings of origins [133].
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Figure 8: Cell cycle components and checkpoints
G1, S, G2 and M constitute the four sequential phases of cell cycle. The cellular progression
through each of these phases is controlled by the action of CDK and its binding partner
cyclin. Upon encountering DNA damage in the G1 phase, the G1 checkpoint is activated
which stops the cells from proceeding into the S phase until the damage is fixed. Problems
encountered during DNA replication or DNA damage in the S phase triggers an intra-S
checkpoint. The G2 checkpoint checks for the completion of DNA replication and size of the
cell before proceeding into mitosis. A spindle checkpoint is activated when the
chromosomes are misaligned.
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1.5: DNA replication
Because faithful duplication of genome is vital for ensuring proper functioning of
cellular processes, and since the duplication process itself is susceptible to cellular
disturbances, the process of DNA replication is tightly controlled. DNA replication can be
divided into three stages: origin licensing, origin firing, and elongation. The first stage or
the licensing of origins occurs in the G1 phase. In the G1 phase, the replicative
minichromosome maintenance (MCM) helicase complex comprising of a hetero-hexameric
ring of the proteins MCM2-7 and its associated factors are loaded onto the DNA. This
loaded complex is called the pre-replication complex (pre-RC) and it marks origins as
licensed. The origin licensing checkpoint ensures the completion of pre-RC loading and only
then it permits the cells to enter S phase. Similar to the G1-S checkpoint, the origin
licensing checkpoint is regulated by p53 and Rb/E2F [134].
Upon entry into the S phase, the replication origins that are organized in clusters, fire
in a time dependent manner. Although the timing allows for the sequential activation of
various clusters, the details of these processes are unclear [134]. The firings of individual
origins within the clusters are mainly regulated by CDK1, 2 and Cdc7 kinases. These kinases
phosphorylate several components of pre-RC and signal for the recruitment of helicase
cofactor cdc45. The cofactor loading renders the helicase active, and it starts unwinding
the DNA [135]. Subsequently, primase/DNA polymerase α complex associate with pre-RC,
and the replication commences upon generating replication bubble in which replication
fork progresses bi-directionally from the origin [136, 137]. Replacement of DNA
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polymerase α with replicative polymerase δ and ε brings about a switch from initiation into
the elongation phase of DNA replication.
1.5.1: Control of replication origin firings and fork stabilization under replication stress
The ATR-Chk1 pathway is a crucial component of general surveillance mechanism of
replication phase and is activated at low levels even during unperturbed S phase [138,
139]. Conditions of replication stress that lead to replication fork stalling result in a full
activation of this pathway. A fully induced ATR and Chk1 activity contributes toward
stabilization of stalled replication fork. Fork stabilization is vital for the cells because they
can resume DNA synthesis once the replication stress is relieved. In addition, fork
stabilization by ATR and Chk1 kinase avoids the occurrences of catastrophic DSBs [140,
141]. The complete picture of how the fork stabilization is accomplished is not unknown
[142]. Besides fork stabilization, the ATR and Chk1 kinase also control the firings of
replication origins in the S phase [143]. A model for the regulation of origin firings and fork
stabilization is shown in (Figure 9).
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Figure 9: Pathway regulating origin firings and fork stabilization under conditions of
replication stress
Replication stress conditions which impede fork movement lead to generation of ssDNA
and activate the ATR-Chk1 pathway. Activated Chk1 and Wee1 inhibit the activity of
Cdk1/2 and Cdc7 and prevent origin firings in previously inactive replication clusters. ATRChk1 pathway also contributes towards fork stability but the exact mechanism is not
known. Stalled forks may lead to an activation of dormant origins within the active cluster
thereby promoting replication despite presence of replication stress.

30

Because the ATR-Chk1 pathway also suppresses origin firings in an unperturbed S
phase, it is natural to expect that conditions of replication stress that fully activate this
pathway should shut down origin firings. However, this is not always the case [144, 145].
This seeming contradiction could be explained by the reasoning that not all origins licensed
during DNA replication fire under normal conditions. In an unperturbed eukaryotic cells,
only 5 to 10% of the licensed origin fire during DNA replication [146]. The unfired or
dormant origins are passively replicated under normal conditions. However, under
conditions of replication stress that causes fork stalling and/or threat to the genome, these
dormant origins fire to ensure successful and complete genomic duplication. It has been
reported that the inhibitory action of the ATR and Chk1 kinases is directed mainly against
the origins of the replication clusters that are not yet activated [146]. Based on the recently
proposed model, the rescue of stalled replication forks is achieved through stochastic firing
of dormant origins near stalled forks, while at the same time the firings of origin within the
so far inactive clusters are inhibited through the action of ATR and Chk1 kinases (Figure 10)
[146].
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Figure 10: Model for regulation of origin clusters under conditions of replication stress
During unperturbed DNA replication (left), clusters containing the origins are activated
serially in temporal manner. Inhibition of replication due to stress or DNA damage (right)
lead to stochastic activation of dormant origins within the active clusters. These dormant
origins are otherwise passively replicated under normal conditions. ATR-Chk1 pathway
activated due to replication stress conditions suppresses origin firings in new inactive
clusters.
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1.6: Checkpoint kinases 1 and 2
1.6.1: Checkpoint kinase 1
Chk1 was first identified by Tony Carr and colleagues about 21 years ago in S. pombe
[147, 148]. Subsequently, the homologs of this kinase were identified in all eukaryotes.
The human Chk1 is a nuclear protein of 476 amino acids containing a highly conserved Nterminal kinase domain (residues 1–289), a flexible linker region, and a less conserved Cterminal region [149, 150]. The C –terminal region, consisting of about 200 residues in all
species, possess two regions of conserved sequences and has been described as a
regulatory domain [147]. The crystal structure of the human Chk1 kinase domain (residues
1–289), but not the full length protein, has been solved [149, 150]. Chk1 catalytic domain
has a canonical kinase structure of two lobe fold with ATP-binding cleft in between the two
lobes as shown in (Figure 11). The conformation of the Chk1 catalytic domain is close to an
open structure, which means that the kinase does not require modification to adopt an
open fold of active kinase. The phosphorylation of Chk1 on the S345 site by upstream ATR
is necessary for Chk1 activation, but the exact mechanism by which this modification
influences the activity of Chk1 kinase is not established [147] (Figure 12). Existing evidence
suggest that the C-terminal domain may be auto-inhibiting N terminal catalytic activity
through physical interaction, as the kinase activity of the isolated catalytic domain was
reported to be substantially elevated over the full length molecule [147]. Studies in cell
free systems have shown that C- and N-terminal domain physically interact and this
interaction can be disrupted by phosphomimetic substitutions at ATR phosphorylation sites
[147].
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Figure 11: Structure of Chk1 kinase domain
The structure of Chk1 kinase domain is similar to that of any kinase with open
conformation. The N- and C-terminal lobes are circled in red and purple, respectively, while
the activation loop in between is circled in blue. The hinge region connecting the two lobes
contains the ATP binding pocket and is indicated by black arrow. Image taken from Zhao,
B., Structural basis for Chk1 inhibition by UCN-01. J Biol Chem, 2002. 277(48): p. 46609-15
with permission.
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Figure 12: Model of Chk1 activation
In an inactive kinase state, the C-terminal regulatory domain covers the catalytic cleft of
the kinase. Phosphorylation of the C-terminal regulatory domain on S345 site by ATR opens
the molecule to expose the catalytic cleft. Image taken from Tapia-Alveal, C., T.M. Calonge,
and M.J. O'Connell, Regulation of chk1. Cell Div, 2009. 4: p. 8.with permission.
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1.6.2: Checkpoint kinase 2
Rad53, the founding member of the Chk2 family of checkpoint kinases, was first
identified in budding yeast 20 years ago. The human homologue, named Chk2 by the
Elledge lab, was identified by five different labs in the year 1998-99 [151]. The human Chk2
protein, also known as hCDS1, is a 543 amino acid protein that consists of three distinct
functional domains; an N-terminal SQ/TQ cluster domain (SCD), a central forkheadassociated (FHA) domain, and a C-terminal serine/threonine kinase domain (KD) [152, 153]
(Figure 13). The five SQ and two TQ sites present within the SCD are the characteristic
phosphorylation sites of ATM, with Thr68 site being the primary phosphorylation site in
response to DNA damage[153]. The phosphopeptide binding FHA domain, which is well
conserved from yeast to humans, is involved in protein-to-protein interactions[153]. In
unperturbed cells, the Chk2 kinase domain is held inactive through auto-inhibition by a
loop within the kinase domain. In response to DNA damage, inactive monomers of Chk2
protein dimerize, which is followed by several phosphorylation events including Thr 383
and Thr 387 on the auto-inhibitory loop. This results in full activation of Chk2 kinase [153].
The schematic steps for Chk2 activation are shown in (Figure 13).
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Figure 13: Functional domain architecture of Chk2 and model of Chk2 activation
The three functional domains of Chk2 include SQ/TQ cluster domain (SCD), forkhead
associated domain (FHA), and the kinase domain. Chk2 exist as monomers in an inactive
state. Radiation induced activation of ATM results in phosphorylation on Thr68 site within
the SCD domain. This triggers Chk2 dimerization, which is then followed by
autophosphorylation and subsequent activation of Chk2 dimers or monomers. Image taken
from Ahn, J., M. Urist, and C. Prives, The Chk2 protein kinase. DNA Repair (Amst), 2004.
3(8-9): p. 1039-47 with permission.
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1.6.3: Chk1, Chk2 and Cancer
Although structurally distinct, Chk1 and Chk2 have overlapping functions in the
cellular processes. These two kinases regulate the fundamental cellular functions of DNA
replication, cell cycle progression, chromatin restructuring and apoptosis [154]. Almost all
cancers show perturbations in these important cellular processes which suggests that
these kinases may be critical targets of alteration during tumorigenesis. Germline mutation
in Chk2 was first observed in the sub-population of Li-Fraumeni syndrome families that
harbored wtp53. This suggested that Chk2 germline mutation may phenocopy p53
inactivation [153, 154]. The Chk2 allele harboring a 1100delC mutation that encoded a
truncated protein was found to confer increased breast cancer risk which was independent
of the mutations seen in BRCA1 and BRCA2 genes [153]. Several missense mutations in
Chk2 have been identified in cancer cell lines and the list of mutations is still expanding
[153, 154]. For these results, Chk2 kinase has been qualified as a tumor suppressor. On the
other hand, the cancer-associated defects in Chk1 kinase are very rare, and so far, the
exceptions seem limited to the tumors exhibiting microsatellite instability[154]. A complete
loss of Chk1 is deleterious for tumor formation; however, a heterozygous loss of Chk1 has
been shown to promote tumorigenesis [154].
1.6.4: Checkpoints as therapeutic target in cancer
Almost all cancer cells harbor defects in their checkpoints and it is probably the most
common distinguishing feature between cancer and normal cells. This has opened up a
possibility for therapeutic intervention. One strategy that has been explored, with
moderately positive outcome in various in-vitro cancer models, is via inhibition of
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checkpoint kinases [154]. The rationale behind the preferential killing of cancer cells with
such strategy is that tumor cells defective in certain checkpoint(s) become addicted to
other intact checkpoint(s) for mounting DDR and inhibition of these remaining checkpoints
would lead to enhanced cell death due to massive accumulation of DNA damage. So far,
this strategy has been employed majorly to target p53 defective cancers that lack G1
checkpoint, and hence dependent on G2 checkpoint for mounting DDR.
Inhibition of G2 checkpoints via inhibition of ATR/ATM (caffeine) and Chk1/2 kinases
(chemical inhibitors like UCN-01) have shown an improvement in the therapeutic activity of
DNA damaging agents[154]. However, both these abrogators of G2 checkpoints were nonselective. The staurosporine derivative UCN-01 was found to inhibit several cellular
kinases, and also bind to plasma proteins, hence was shelved due to limited clinical
application. The development of second generation checkpoint kinase inhibitors with
better selectivity profiles has rekindled the interest to test these small molecule inhibitors
in combination with genotoxic agents in various cancer models. A number of in-vitro and
in-vivo studies have shown promising preclinical activities of these inhibitors in
combination with range of genotoxic agents [155-160]. Recently, checkpoint inhibitors
were reported to have synergistic effect on cancer cell killing when combined with
inhibitors targeting important cell cycle proteins such as Wee1 kinase [161]. Intriguingly, in
some in-vitro cancer models, Chk1 inhibitors were shown to be effective as single agent
[162, 163].
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1.6.5: Checkpoint kinase inhibitors
A number of compounds inhibiting Chk1/2 kinases are at various stages of early
clinical trials (Table1) [164]. The majority of these are ATP competitive inhibitors that bind
to the hinge region found between the C-terminal and N-terminal lobes of the kinase
domain [165]. The hinge region contains residues that are non-conserved across the
kinases, and binding to this region imparts specificity to these second generation
checkpoint inhibitors.
Table 1: Chk1/2 inhibitors in clinical trials
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1.6.5.1: AZD7762
A high throughput screen of Astra Zeneca’s collection of compounds followed by a hit
to lead identification and optimization using protein-ligand structures for rational
compound design and optimization yielded a thiophene carboxamide urea derivative
AZD7762

(3-(carbamoylamino)-5-(3-fluorophenyl)-N-[(3S)-3-piperidyl]thiophene-2-

carboxamide]), a potent ATP competitive, dual inhibitor of Chk1 and Chk2 kinases [165,
166] (Figure 14). The inhibitor IC50 for Chk1 and Chk2 was found to be 5 nM and <10 nM,
respectively. The inhibitor selectivity was found to be greater than 1000 fold against
Cdk1/Cyclin B1 [166] and greater than 100 fold selectivity was observed against multiple
protein kinase C isoforms, other CDKs, p38 (all isoforms), and MAPKAPK2.
The Chk1 bound X-ray structure of the inhibitor revealed that the urea carbonyl and
terminal amino functional groups were contacting Cys87 and Glu85 at the hinge and the
amide group pointed towards the ribose pocket (Figure 15) [165, 166]. These interactions,
together with the new polar interactions between the cyclic amine and Asp148, and
dipole-dipole interactions with the backbone carbonyl of Glu134 and the amide side chain
of Asn135, conferred increased potency to the drug. The 3-fluorophenyl moiety offered fair
balance of property to the drug. Several studies have reported that AZD7762 synergizes
with a number of known cytotoxic agents in a spectrum of tumor models [155, 160].
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Figure 14: Formula structure of AZD7762
Image taken from Oza, V, Discovery of checkpoint kinase inhibitor (S)-5-(3-fluorophenyl)-N(piperidin-3-yl)-3-ureidothiophene-2-carboxamide (AZD7762) by structure-based design
and optimization of thiophenecarboxamide ureas. J Med Chem, 2012. 55(11): p. 513042.with permission.
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Figure 15: X ray crystal structure of AZD7762 in complex with Chk1 kinase
The part of the Chk1 kinase protein depicted above is oriented such that the N-terminal
lobe is toward left and C terminal lobe is toward bottom right and the hinge region is at the
lower left. Protein backbone strands and carbon atoms in the protein are colored in wheat
and nitrogen atom is in red. The carbon atoms of the inhibitor are colored in green,
nitrogen atoms are in red, oxygen atoms in dark blue, and fluorine atom in light blue. The
hydrogen bonds are shown in dotted blue lines. Image captured with permission from Oza,
V. Discovery of checkpoint kinase inhibitor (S)-5-(3-fluorophenyl)-N-(piperidin-3-yl)-3ureidothiophene-2-carboxamide (AZD7762) by structure-based design and optimization of
thiophenecarboxamide ureas. J Med Chem, 2012. 55(11): p. 5130-42.
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1.6.5.2 LY2606368
As reported by Eli Lilly and Company, LY2606368 is a potent, second generation
selective ATP competitive inhibitor of the Chk1 protein kinase with an IC 50 of less than
1nM. The inhibitor IC50 for Chk2 kinase is 4.7 nM. Structurally, LY2606368, is a
cyanopyrazine derivative[165].

However, the medicinal chemistry steps involved in

synthesizing this molecule are not known. Also, the X ray crystal structure of LY2606368
bound Chk1 has not been revealed. Studies investigating LY2606368 have reported
inhibition of cell proliferation in a variety of pancreatic cell lines when used as a single
agent. Furthermore, preclinical studies conducted by the company reported inhibition of
tumor growth with LY2606368 monotherapy or in combination with DNA damaging agents
in subcutaneous xenograft and orthotopic in vivo models of ovarian and pancreatic cancer
(AACR; Mol Can Ther 2011; 10(11 Suppl): Abstract # A108 and AACR; Cancer Res 2012; 72(8
Suppl): Abstract # 1776)
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Figure 16: Formula structure of LY2606368
Image captured from Matthews, T.P., A.M. Jones, and I. Collins, Structure-based design,
discovery and development of checkpoint kinase inhibitors as potential anticancer
therapies. Expert Opin Drug Discov, 2013. 8(6): p. 621-40 with permission.
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HYPOTHESIS
In the current study, we hypothesize that HNSCC cells respond to cisplatin in a p53
dependent manner. We further hypothesize that cisplatin resistance of HNSCC cells could
be overcome through inhibition of Chk1/2 kinases.
Next, we hypothesize that a significant subset of HNSCC cells are hypersensitive to
Chk1 inhibition and this acute sensitivity to Chk1 inhibition in a subset of HNSCC cells is due
their inability to deal to replication stress.
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CHAPTER 2: MATERIALS AND METHODS
2.1: Materials
2.1.1: Technical devices
Table 2: Technical Devices

Device

Company

Blotting Chamber

Bio-Rad, Hercules, CA, USA

Centrifuge Marathon 21000R

Thermo Scientific ,Waltham, MA, USA

Centrifuge- Sorvall RT6000B

DuPont-Sorvall, USA

CO2 water jacketed incubator for cell
culture
Electrophoresis system, for SDS-PAGE

Thermo Scientific ,Waltham, MA, USA

Electroporator - Nucleofector II machine

Basel, Switzerland

FACS Calibur

BD Biosciences, San Jose, CA

FACS Fortessa

BD Biosciences, San Jose, CA

Freezer -20 degree Celsius

Panasonic, Kadoma, Osaka, Japan

Freezer -80 degree Celsius

Thermo Scientific ,Waltham, MA USA

Heating Block

Thermo Scientific, Waltham, MA, USA

HP Scanjet 5590

Hewlett Packard, Paolo Alto, CA, USA

Ice Maker F-300 BAF
Laminar flow cabinet

Hoshizaki America Inc., South Peachtree City,
GA
NuAire, Plymouth, MN, USA

Liquid nitrogen tank 810 Eterne

MVE Biological systems, Ball Ground, GA, USA

Magnetic stirrer

Thermo Scientific, Waltham, MA, USA

Microcentrifuge 300D

Denville Scientific, South Plainfield, NJ, USA

Microplate reader EL808

Biotek Instruments, Winooski, VT , USA

Microscope (80i)

Nikon, Chiyoda, Tokyo, Japan

Bio-Rad, Hercules, CA, USA
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Microscope (Inverted)

Zeiss

Microscope (IX71)

Olympus, Center Valley, PA, USA

Microscope (IX81-DSU Spinning disk
confocal microscope)
Personal Computer

Olympus, Center Valley, PA, USA

pH meter

Thermo Scientific ,Waltham, MA, USA

Pipet- electric portable

Drummond, Broomall, PA, USA

Pipet-multichannel

Eppendorf, Hamburg, Germany

Pipets (0.1 - 2.5μl; 0.5 - 10 μl; 10-100 μl;
100-1000 μl)
Refrigerator 4 degree Celsius

Gilson Pipetman, Middleton, WI, USA

Shaker (Genemate orbital shaker OS30)

Denville Scientific, South Plainfield NJ, USA

Sonication device (model 100)

Thermo Scientific, Waltham, MA, USA

Timer

Thermo Scientific, Waltham, MA, USA

UV- chamber GS gene linker

Bio-Rad, Hercules, CA, USA

Vortex

Thermo Scientific, Waltham, MA, USA

Water Bath

Thermo Scientific, Waltham, MA, USA

Xomat- Film processor 2000A

Kodak, Rochester, NY,USA

Dell, Round Rock, TX, USA

Kenmore, Hoffman Estates, IL , USA

2.1.2: Consumables
Table 3: Consumables

Product

Company

Cell culture dishes (6 cm, 10 cm,
15 cm)
Cell culture plates (6 well, 96
well)
Cell scraper

Corning Inc, Corning, NY, USA

Conical tubes (15 ml, 50 ml)

Corning Inc, Corning, NY, USA

Cover Slips

Thermo Scientific, Waltham, MA, USA

Corning Inc, Corning, NY, USA
Corning Inc, Corning, NY, USA
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Cryo tubes

Corning Inc, Corning, NY, USA

Filter tips (10, 20, 200, 1000 μl)
Microscopy Glass Slide superfrost

VWR, Radnor, PA, USA and Thermo Scientific,
Waltham, MA, USA
Thermo Scientific, Waltham, MA, USA

Nitrile Hand Gloves

Medline, Mundelein, IL, USA

Nitrocellulose transfer membrane Thermo Scientific, Waltham, MA, USA
Parafilm

Bemis, Neenah, WI, USA

Pipet tips (10, 20, 200, 1000 μl)
Polyvinyl chloride wrap

Greiner Bio- One and Thermo Scientific, Waltham,
MA, USA
Thermo Scientific, Waltham, MA, USA

Reaction tube (1.5 ml, 2 ml)

Eppendorf, Hamburg, Germany

Sealing aluminium foil

Bio-Rad, Hercules, CA, USA

Sterile filter

Thermo Scientific, Waltham, MA, USA

Sterile glass pipets

Greiner Bio-One, Monroe, NC, USA

Syringe

Thermo Scientific, Waltham, MA, USA

Whatman paper

Thermo Scientific, Waltham, MA, USA

2.1.3: Chemicals and Reagents
Table 4: Chemicals and Reagents

Chemical

Company

Acetic acid

Thermo Scientific, Waltham, MA, USA

Acrylamide solution 39%

Bio-Rad, Hercules, CA, USA

Bovine Serum Albumin (BSA)

Sigma- Aldrich, St. Louis, MO, USA

Ammonium persulphate (APS)

Thermo Scientific, Waltham, MA, USA

Bromodeoxyuridine (BrdU)

Sigma- Aldrich, St. Louis, MO, USA

Chlorodeoxyuridine (CldU)

Sigma- Aldrich, St. Louis, MO, USA
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Protease inhibitor tablets

Thermo Scientific, Waltham, MA, USA

Crystal Violet

Sigma- Aldrich, St. Louis, MO, USA

Dimethyl sulphoxide (DMSO)

Thermo Scientific, Waltham, MA, USA

Ethanol 200 Proof (EtOH)

Pharmco-Aaper, Brookfield CT, USA

Formaldehyde, 37 % solution

Sigma- Aldrich, St. Louis, MO, USA

Glycerol

Thermo Scientific, Waltham, MA, USA

Hydrogen Chloride

Thermo Scientific, Waltham, MA, USA

Methanol >99% (MetOH)

Thermo Scientific, Waltham, MA, USA

Nailpolish

ELF, USA

Nonyl phenoxypolyethoxylethanol (NP-40)

Sigma- Aldrich, St. Louis, MO, USA

Nuclease free water

Life Tech., Grand Island, NY, USA

RNAse free water

Qiagen, Venlo, Limburg

Fluorescein phalloidin (FITC- Phalloiden)

Sigma- Aldrich, St. Louis, MO, USA

Ponceau S

Sigma- Aldrich, St. Louis, MO, USA

Prestained protein ladder

Thermo Scientific, Waltham, MA, USA

Propidium iodide

Sigma- Aldrich, St. Louis, MO, USA

Sodium bicarbonate

Sigma- Aldrich, St. Louis, MO, USA

Sodium fluoride

Sigma- Aldrich, St. Louis, MO, USA

Sodium chloride

Thermo Scientific, Waltham, MA, USA

Sodium deoxycholate

Sigma- Aldrich, St. Louis, MO, USA

Sodium dodecyl suphate (SDS)

Thermo Scientific, Waltham, MA, USA

Sodium hydroxide (NaOH)

Sigma- Aldrich, St. Louis, MO, USA

Sodium orthovanadate

Sigma- Aldrich, St. Louis, MO, USA

Tetramethylethylenediammine (TEMED)

Thermo Scientific, Waltham, MA, USA

Thymidine

Sigma- Aldrich, St. Louis, MO, USA
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Trisamine (Tris)

Sigma- Aldrich, St. Louis, MO, USA

Triton X-100

Thermo Scientific, Waltham, MA, USA

Tween 20

Thermo Scientific, Waltham, MA, USA

4',6-diamidino-2-phenylindole (DAPI)
vectashield mounting medium
β- mercaptoethanol

Vector laboratories, Burlingame, CA,
USA
Sigma- Aldrich, St. Louis, MO, USA

Staurosporine

Sigma- Aldrich, St. Louis, MO, USA

2.1.4: Buffers and Solutions
Table 5: Buffers and Solutions

Radioimmunoprecipitation base
(RIPA)
Tris pH 7.4

1M

Sodium chloride

1.5M

Sodium deoxycholate

0.50%

EDTA

500 mM

NP40

0.01%

Dissolved in ddH2O

RIPA Lysis Buffer, pH 7.4
Protease inhibitor

1X

Sodium fluoride

10 mM

Sodium orthovanadate

1 mM

Sodium pyrophosphate

5 mM

dissolved in RIPA
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Crystal Violet solution
Crystal Violet

1. 5%

Methanol

25%

Diluted in ddH2O

Ponceau S solution
Ponceau S

0.50%

Acetic Acid

1%

Dissolved in ddH2O

Tris buffered saline + Tween 20 (TBST), pH
7.6
Tris

50 mM

Sodium chloride

150 mM

Tween 20

0.10%

SDS sample buffer (5X)
Tris-HCl (pH 6.8)

250mM

SDS

10%

Glycerol

50%

Bromophenol blue

0.02%

β-mercaptoethanol

10%

Western blot blocking solution
Non-fat dry milk

5%
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dissolved in TBST
Western blot running buffer
Tris Base

25 mM

Glycine

0.2 M

SDS

3.5
mM

Western blot transfer buffer
Tris Base

24 mM

Glycine

0.2 M

Methanol

20%

Senescence staining solution
Citric acid/sodium phosphate solution (pH 6)

40 mM

Sodium chloride

0.15 M

Magnesium chloride

0.20%

X-gal (dissolved in dimethylformamide)

1 mg/mL

Potassium ferrocyanide

1%

Potassium ferricyanide

1%

Dissolved in H20

PI solution
PI powder

1mg/mL

Citric acid

0.10%

Triton-X 100

0.10%

Dissolved in H20
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Sodium chloride

0.15 M

Lysis buffer for DNA fiber analysis
SDS

0.50%

Tris -HCL, pH 7.4

200mM

EDTA

50 mM

2.1.5: Kits
Table 6: Kits

Name

Company

Amersham ECL Western Blotting Detection
Reagents
Cell Line Optimization Nucleofector™ Kit for
Nucleofector™ Device
DeadEnd™ Fluorometric TUNEL System

GE Healthcare lifesciences, Cleveland,
Ohio, USA
Basel, Switzerland

FITC-BrdU Flow Kit

BD Biosciences, San Jose, CA

Pierce ECL Western Blotting Substrate

Thermo-Scientific, Lafayette, CO, USA

Pierce™ BCA Protein Assay Kit

Thermo-Scientific, Lafayette, CO, USA

Senescence β-Galactosidase Staining Kit

Cell Signaling, Danvers, MA, USA

Madison, WI, USA

2.1.6: Chemotherapeutics and Inhibitors
Table 7: Chemotherapeutics and Inhibitors

Commercial Name

Target

Company

AZD7762

Chk1 and Chk2

Astra Zeneca, Boston, MA, USA

ETP-46464

ATR

Selleckchem, USA

LY2606368

Chk1

Eli Lilly, Indianapolis, IL, USA

Roscovitine

Cdk 1, 2, 5, 7 and 9

Selleckchem, USA

MK-1775

Wee1

Merck
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2.1.7: Oligonucleotides
Table 8: Oligonucleotides

Name (Identifies
Target)

Catalogue
number

Company

Scramble/non Targeting

4390846

CHEK1

SI00299859

Life Technologies, Carlsbad, CA,
USA
Qiagen, Venlo, Limburg

CHEK2

SI02224271

Qiagen, Venlo, Limburg

ATR

M-003202-05-0005

ATM

SI00299299

Thermo-Scientific, Lafayette, CO,
USA
Qiagen, Venlo, Limburg

CDK1

SI00299712

Qiagen, Venlo, Limburg

CDK2

M-003236-04-0005

Thermo-Scientific, Lafayette, CO,
USA

2.1.8: Antibodies
Table 9: Primary Antibodies

Target

Dilution

Catalogue
number

Company

Anti-BrdU antibody
(mouse)

1 to 150

347580

BD Biosciences, San Jose, CA

Anti-BrdU antibody
[BU1/75 (ICR1)] (RAT)
ATM

1 to 150

ab6326

Abcam, Cambridge, England

1 to 1000

2873

ATR

1 to 500

2790

Aurora kinase B (Thr232)

1 to 1000

2914

cdk1

1 to 1000

9116

cdk2

1 to 1000

2546

Cell Signaling, Danvers, MA,
USA
Cell Signaling, Danvers, MA,
USA
Cell Signaling, Danvers, MA,
USA
Cell Signaling, Danvers, MA,
USA
Cell Signaling, Danvers, MA,
USA
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Chk1

1 to 1000

2345

Chk2

1 to 1000

2662

Fluorochromeconjugated anti-BrdU
Antibody
H3

1 to 50

559619

1 to 1000

9717

p21

1 to 750

2946

P53

1 to 1000

sc-126

PARP

1 to 1000

9532

pATM (S1981)

1 to 1000

5883

pcdk1(Thr161)

1 to 1000

9114

pcdk2(Thr160)

1 to 1000

2561

pChk1 (S296)

1 to 1000

2349

pChk1 (S345)

1 to 1000

2348

pChk2 (Thr68)

1 to 1000

2661

PCNA

1 to 500

MAB424R

pH3 (S10)

1 to 1000

9701

pHSP27(S82)

1 to 500

ab155987

polH

1 to 250

sc-17770

pP53(S15)

1 to 1000

9284

RPA34

1 to 1000

NA19L

β-Actin

1 to 5000

sc-47778

γH2AX (S139)

1 to 1000

9718
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Cell Signaling, Danvers, MA,
USA
Cell Signaling, Danvers, MA,
USA
BD Biosciences, San Jose, CA

Cell Signaling, Danvers, MA,
USA
Cell Signaling, Danvers, MA,
USA
Santa Cruz Biotechnology,
Santa Cruz, CA, USA
Cell Signaling, Danvers, MA,
USA
Cell Signaling, Danvers, MA,
USA
Cell Signaling, Danvers, MA,
USA
Cell Signaling, Danvers, MA,
USA
Cell Signaling, Danvers, MA,
USA
Cell Signaling, Danvers, MA,
USA
Cell Signaling, Danvers, MA,
USA
EMD Millipore, Billerica, MA,
USA
Cell Signaling, Danvers, MA,
USA
Abcam, Cambridge, England
Santa Cruz Biotechnology,
Santa Cruz, CA, USA
Cell Signaling, Danvers, MA,
USA
EMD Millipore, Billerica, MA,
USA
Santa Cruz Biotechnology,
Santa Cruz, CA, USA
Cell Signaling, Danvers, MA,
USA

Table 10: Secondary Antibodies

Target

Dilution

Alexa Fluor 488 Goat AntiRat IgG (H+L)
Alexa Fluor 568 Goat AntiMouse IgG (H+L)
Goat anti-rabbit IgG-HRP
Goat anti-mouse IgG-HRP

Catalogue
number

1 to 150

A-11001

1 to 200

A-11004

1 to 5000

sc-2004

1 to 5000

sc-2005

Company
Life Technologies, Carlsbad,
CA, USA
Life Technologies, Carlsbad,
CA, USA
Santa Cruz Biotechnology,
Santa Cruz, CA, USA
Santa Cruz Biotechnology,
Santa Cruz, CA, USA

2.1.9: Media and cell culture reagents
Table 11: Media and Culture Reagents

Media and Reagents

Company

Amino Acids

Thermo Scientific ,Waltham, MA, USA

Dulbecco’s Modified Eagle Medium (DMEM)
Fetal Bovine Serum (FBS)

Gibco, Life Technologies, Carlsbad, CA,
USA
Thermo Scientific ,Waltham, MA, USA

Hydrocortisone

Thermo Scientific ,Waltham, MA, USA

L-Glutamine

Thermo Scientific ,Waltham, MA, USA

McCoy’s Medium
Penicillin/Streptomycin

Gibco, Life Technologies, Carlsbad, CA,
USA
Thermo Scientific ,Waltham, MA, USA

Pyruvate

Thermo Scientific ,Waltham, MA, USA

RPMI Medium
Trypsin/EDTA

Gibco, Life Technologies, Carlsbad, CA,
USA
Thermo Scientific ,Waltham, MA, USA

Vitamins

Thermo Scientific ,Waltham, MA, USA
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2.1.10: HNSCC cell lines
Table 12: HNSCC cell lines

Name

Origin

p53 status

183

Oropharynx

Mutated

1483

Oral cavity

Mutated

584 A2

Larynx

Mutated

Ca922

info not available

Mutated

Cal27

Oral cavity

Mutated

Det562

pharynx

Mutated

FADU

Hypopharynx

Mutated

HMS-001

info not available

HN30

pharynx

Wild type (not
expressed)
Wild type

HN31

lymph node metastasis

Mutated

HN4

Larynx

Mutated

HN5

Oral cavity

Mutated

HOSC1

Oral cavity

Mutated

JHU011

Larynx

Mutated

JHU022

Larynx

Mutated

JHU029

Larynx

Mutated

MDA 1386 LN

Hypopharynx

Mutated

MDA 1683

info not available

Mutated

MDA 1986 LN

Oral cavity

Mutated

MDA 686 LN

Oropharynx

Mutated

MDA 686 TU

Oropharynx

Mutated

MDA1386 TU

Hypopharynx

Mutated
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MDA1586

Larynx

Mutated

MSK922

info not available

Mutated

OSC19

Mutated

PCI15A

right lateral margin of the
tongue
Oral cavity

PCI15B

Oral cavity

Mutated

PCI24

Oral cavity

Mutated

PJ 34

Oral cavity

Mutated

SCC61

Oral cavity

Mutated

SQCCY1

Oral cavity

Mutated

TR146

Oral cavity

Mutated

TU138

Oral cavity

Mutated

UMSCC 22A

Hypopharynx

Mutated

UMSCC 47

Oral cavity

UMSCC 85

nasal vestibule

Wild type (not
expressed)
Mutated

UMSCC1

Oral cavity

Mutated

UMSCC10A

Larynx

Mutated

UMSCC10B

Larynx

Mutated

UMSCC14A

Floor of mouth

Mutated

UMSCC-14B

Floor of mouth

Mutated

UMSCC17A

Larynx

Wild type

UMSCC17B

Larynx

Mutated

UMSCC19

Oropharynx

Mutated

UMSCC22B

Hypopharynx

Mutated

UMSCC25

Larynx

Mutated

UMSCC3

info not available

Mutated
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Mutated

UMSCC33

maxillary sinus

Mutated

UMSCC4

Oropharynx

Mutated

UMSCC6

Oropharynx

Mutated

2.1.11: Software
Table 13: Softwares

Name

Company

FlowJo software

TreeStar, Ashland, OR, USA

ImageJ software

National Institutes of Health, Bethesda, MD, USA

Adobe Photoshop CS5

Adobe Systems, San Jose, CA, USA

Microsoft Excel 2010

Microsoft, Redmond, WA, USA

Karyotyping software

Applied Spectral Imaging (ASI) Inc., Vista, CA, USA
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2.2: Methods
2.2.1: Drug dilutions for usage
AZD7762, LY2606368, Roscovitine, ETP-46464 and MK-1775 were received from the
company in powder form. Drugs were then dissolved in 100% dimethyl sulfoxide (DMSO)
to a stock concentration of 10 mmol/L (AZD7762), 20 mmol/L (LY2606368), 20 μmol/L
(Roscovitine), 20 mmol/L (ETP-46464), and 10mmol/L (MK-1775). Drugs were then stored
in aliquots at recommended temperatures.
2.2.2: Culturing of HNSCC cell lines
HNSCC cell lines used for our study were obtained from an established cell bank in
the laboratory of Dr. Jeffrey Myers (University of Texas MD Anderson Cancer Center,
Houston, TX) under the approved institutional protocols. These cell lines were tested and
authenticated against the parental cell lines using short-tandem repeat analysis within 6
months of use for the current study. Cell lines were cultured in DMEM, McCoy’s or RPMI
growth medium. Appropriate supplements were added to culture media for optimal
cellular growth. HN30-shp21 and HN30-shp53 cell lines were generated from a lentiviral
stable knockdown of p21 and p53, respectively, in HN30 cells as described previously.
2.2.3: Proliferation and Survival assays
2.2.3.1 MTT assay
MTT assays were performed on 96 well plates. Roughly, 1000-3000 cells were seeded
in quadruplicates under each treatment in 96 well plates. Next day, a day zero OD reading
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was assessed in the following manner. 25 μL of MTT reagent was added to media over the
cells in a 96 well plate and incubated for 2 hrs at 37 0C . The media-reagent mixture was
then discarded, and cells were incubated with 100 μL DMSO (100%) to lyse the cells. The
released formazan dissolves in DMSO, and gives purple color. The colorimetric OD reading
was taken on microplate reader. At day zero, the remaining plates were exposed to various
treatments for given time period as indicated. At day 5, all the plates were processed in a
similar manner as day zero and OD values were obtained. IC50 values were obtained by
plotting cell viability curves on GraphPad Prism using the net OD values (difference
between day 5 and day zero reading under condition).
2.2.3.2 Clonogenic assay
Clonogenic assays were conducted on 6-well plates. Plating efficiency for each HNSCC
cell line was determined by seeding the cells at different numbers in the wells and allowing
them to form colonies over 14 days incubation. Roughly, 500 to 600 cells per well were
found to be good plating number for each cell line. For each drug titration experiments,
HNSCC cells in logarithmic growth phases were trypsinized, counted, and seeded. Cells
were then allowed to attach overnight. Next day, serial dilutions of drugs were prepared in
culture media and cells were exposed to different drug concentrations. The cisplatin
exposure to cells was for twenty four hours while AZD7762, LY2606368, Roscovitine and
ETP-46464 were exposed for forty eight hours. At the end of the treatment, drugs were
removed by sucking off the media and washing the cells with PBS at least two times. Cells
were then supplied with fresh media and allowed to form colonies. At day 14, media was
removed and cell colonies were fixed in cold methanol and stained with crystal violet
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solution. The colony pictures were taken (Alpha Innotech), and analyzed using ImageJ
software. For clonogenic assays with cisplatin plus AZD7762 combination treatment, cells
were treated with cisplatin and AZD7762 concurrently for 24 hours. After 24 hours, media
was aspirated and cells were washed with PBS three times. Cells were then supplied with
fresh media containing AZD7762 (100 nmol/L) for another 24 hours. At the end of the
treatment, cell were washed with PBS and fed with fresh media. Colonies were allowed to
form and processed as described earlier. For clonogenic assays with Roscovitine plus
LY2606368, cells were pre-exposed to Roscovitine (5 μmol/L) for two hours. At the end of
two hours, media was aspirated, and the cells were then treated with Roscovitine (5
μmol/L) and LY2606368 (3 nmol/L) concurrently for 48 hrs. At the end of the treatment,
cell were washed with PBS, fed with fresh media and allowed to form colonies.
2.2.4: Cell cycle analysis
HNSCC cells (3–5 x 104) were plated in 60-mm dish, and allowed to attach overnight.
The next day, cells were exposed to various treatments as indicated. At each indicated time
point, cell media was collected and saved. Cells were then washed with PBS and
trypsinized. The collected media was used to neutralize the trypsin, and cells were spun
down into a pellet. After removing the media, the cell pellet was washed with cold PBS two
times and spun down once again. PBS was then removed and cells were transferred to
bench top, where they were fixed as a single cell suspension in 70% ethanol by gentle
vortexing. The cells were kept at room temperature for 30 minutes or transferred directly
to 40C refrigerator for overnight incubation. On the day of flow cytometry analysis, cells
were first spun down and ethanol was removed. Cells were then stained with PI solution
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containing RNAse A (1mg/mL) and transferred to flow cytometry tubes. Cell cycle
assessment was performed on XL flow cytometer or FACS Calibur or FACS Fortessa
analyzer. The cell cycle data was analyzed on FlowJo software.
2.2.5: Generating cell lysates for SDS-PAGE analysis
HNSCC cells were exposed to various treatments, and at indicated time points, cells
were lysed using RIPA lysis buffer. The cells were scraped off the plate and the lysates
were transferred into eppendorf tubes on ice. The cell lysates were pulse sonicated,
vortexed and proteins were allowed to solubilize in the buffer for 20 minutes. Lysates were
then centrifuged at 14,000 rpm at 40C for 20 minutes and supernatant was collected.
Protein quantification was carried out using Pierce™ BCA Protein Assay Kit and the lysates
were subsequently diluted to a concentration of 1 μg/μl.
2.2.6: Protein separation by SDS-PAGE
Described first by Laemmli in 1970, the SDS-PAGE technique is used to separate
proteins under denaturing condition [167]. This technique involves boiling protein lysates
in the presence of SDS for denaturation. During SDS denaturation, proteins attain an
overall negative charge that is proportional to the protein’s molecular weight. Under an
electric field, the proteins inside the bisacrylamide gel travel towards the anode and
protein separation occurs based on their electrophoretic mobility which is function of their
molecular weight. Thus, the low molecular weight proteins travel faster through the pores
of the gel while the larger proteins move slowly through the gel. The bisacrylamide gels
are composed of two layers, the separation gel and the stacking gel. The stacking gel (5 %
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bisacrylamide) facilitates the focusing of the loaded protein sample. The concentration of
acrylamide in separation gel can be from 8 to 15% depending on the desired protein
resolution. A pre-stained protein ladder is loaded into one of the gel pockets to monitor
protein separation and to estimate their size. For our experiments, the prepared cell
lysates were loaded into the gel pockets in equal volumes and the protein separation was
carried out under an electric field of constant 80 to 100V.
2.2.7: Immunoblotting
Proteins separated by SDS-PAGE were visualized by western blotting to assess protein
levels or their post-translational modifications. Published originally by Renart and
colleagues [168], this method was further developed by Towbin and colleagues [169]. In
this method, a combination of two antibodies is used to detect the proteins of interest
after their transfer from the gel onto an appropriate protein binding membranes. We
assessed the quality of protein transfer onto the membranes by staining membranes with
Ponceau S solution. Before antibody incubations, membranes were blocked with 5% milk in
0.1% TBST. The blocking masks all unbound surface of the membranes, and helps to reduce
background signal. After blocking, membranes were incubated with primary antibody
(diluted to appropriate concentration) that binds to an epitope of a target protein. The
primary antibody incubation was overnight at 40C. After quick washing in TBST,
membranes were incubated with a second antibody that specifically recognizes the
constant region of the first antibody. This second antibody is coupled to horseradish
peroxidase (HRP). HRP oxidizes luminol substrate and emits luminescence signal which is
then detected on autoradiographic film. The membrane blots after washing with TBST
65

were briefly incubated with enhanced chemiluminescence (ECL) reagent (GE Healthcare
Life Sciences) and developed by exposing to X-ray film.
2.2.8: Senescence β-galactosidase assay
HNSCC cells (4 x 104) were seeded in a 6-well plate and allowed to attach overnight.
Next day, cells were treated with the cisplatin at 1.5 μmol/L for 24 hrs. After treatment,
cisplatin was washed out by with PBS and cells were then supplied with fresh media. At day
4 or 6, cells were exposed to a fixative for 10 minutes, washed again with PBS and
incubated with 1ml senescence staining solution. The plate was kept at 370C for 16hrs to
detect senescence-associated β-galactosidase (SA-β-Gal). In each treated or untreated
well, four random field selections were made and the number of SA-β-Gal–positive
(staining blue) were counted under high powered microscope (Olympus, IX71). Percentage
of SA-β-Gal–positive cells was measured as a ratio of blue cells to the total cell counted in
each field multiplied by 100.
2.2.9: Immunofluorescence
HNSCC cells (20 – 40 X 103) were seeded on glass coverslips and allowed to attach
overnight. Next day, cells were exposed to various treatments as indicated. Cells were then
fixed in a 1:1 mixture of methanol: acetone for 10 minutes. Cells were then washed several
times with PBS and permeabilized using 0.1% Triton-X for 5 minutes. Cells were again
washed with TBST and incubated with FITC conjugated-phalloidin for 45 minutes at room
temperature. Cells were then washed with TBST three times. The coverslips were then
mounted on standard glass slides using DAPI-Vectashield mounting medium. Using high

66

powered microscope (Hamamatsu orca ER; Leica), multiple representative photographs in
the field were taken. For quantification of mitotic catastrophe, a total of about 200 cells
were counted across four different fields under each treatment condition in two
independent experiments. Multinucleated cells were counted as cells containing greater
than two nuclei and graphed as a percentage of total number of cells.
2.2.10: TUNEL assay
DeadEnd Fluorometric TUNEL System was used for apoptosis detection. This method
relies on the activity of the enzyme terminal deoxynucleotidyl transferase (TdT) for
apoptosis detection. During apoptosis, a high number of double-stranded DNA ends are
generated as a result of fragmentation of genomic DNA by caspase activated DNase. Thus,
as a hallmark of apoptosis, the genomic fragmentation can be used to identify apoptotic
cells. In the TUNEL assay, TdT recognizes DNA nick ends and attaches a labeled dUTP to
them. A subsequent staining then allows for visualization of apoptotic cells.
Briefly, 40 x 103 HN30 cells were seeded on glass coverslips inside 6-well plates. Cells
were allowed to attach overnight. Next day, cells were treated with 1.5 μmol/L cisplatin for
24 hours. At indicated time points, cells were washed three times in PBS, fixed in 4%
methanol-free formaldehyde for 25 minutes at 40C, washed again, then permeabilized in
0.2% Triton X-100 in PBS for 5 minutes. After permeabilization, cells were equilibrated in
equilibration buffer for 5 minutes at room temperature and then incubated with a buffer
containing nucleotide mix and rTdT enzyme for 1 hour. Cell nuclei were stained with DAPI.
Fluorescence microscopy was conducted using Olympus IX81-DSU Spinning disk confocal
microscope and images were taken with Hamamatsu ORCA II ER camera.
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2.2.11: siRNA knockdown experiment
All siRNA experiments in this study were conducted on nucleofector II machine for
electroporation. Buffer type and optimal program for transfection for each cell type was
identified using cell line optimization kit. The schema for optimization is shown Table 14. 2
μg of pmaxGFP plasmid was used for optimization. The program and the buffer identified
during optimization for a cell line was then used for siRNA knockdown experiments.
For siRNA knockdown experiment, the cells were first trypsinized, neutralized with
media and counted. Roughly, 1 X 106 – 5 X 106 cells were used per electroporation
reaction. After washing cells two times with PBS, they were re-suspended in 100 μL of
nucleofector buffer. 1.5 μg of target siRNA was added to this mixture and the mix was
transferred into electroporation cuvette. The cells were then immediately electroporated
with the optimized program. During each siRNA experiment, a GFP electroporation was
performed as a positive control to assess the efficiency of transfection. After
electroporation, warm media was added quickly to the cuvette. The cells were counted
and seeded for clonogenic, western blot or MTT assay. To confirm target knockdown, the
proteins were harvested 25-40 hrs post electroporation, then resolved by SDS-PAGE and
analyzed by western blotting.

68

Table 14: Optimization scheme for choosing buffer and program for siRNA knockdown
experiment
Buffer L or Buffer V
Program

GFP plasmid (0.5 μg/μl)

A-020

+

T-020

+

T-030

+

X-001

+

X-005

+

L-029

+

D-023

+

T-020

-

-

+

2.2.12: BrdU incorporation assay
FITC-BrdU Flow Kit was used to assess cell cycle kinetics under various treatment
conditions. In this method, Cells entering and progressing through the S phase of the cell
cycle incorporate BrdU (a thymidine analogue) into the newly synthesized DNA. The
incorporated BrdU is probed with anti-BrdU fluorescent antibodies and levels of the cells
associated BrdU are then measured by flow cytometry. With this method, it is also possible
to enumerate the population of cells in different phase of cell cycle by combining BrdU
staining with 7-aminoactinomycin D (7-AAD) staining that binds to total DNA. In our study,
cells were seeded at same density and exposed to various treatments the next day. At the
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indicated time points, the cells were pulse labelled with BrdU (10 μM) for 40 min, after
which the cells were trypsinized, washed in PBS and fixed overnight at 4 0C in the provided
fixative. The cells were washed and permeabilized in a different buffer. After
permeabilization, cells were washed again and treated with DNase to expose BrdU
epitopes. The cells were then incubated with Fluorochrome-conjugated anti-BrdU Antibody
for 20 minutes. After subsequent washing, the cells were stained with 7-AAD in staining
buffer and taken over for analysis on FACS Fortessa flow cytometer. The data was analyzed
on FlowJo software.
2.2.13: Metaphase chromosomal breaks assessment
The control and LY2606368 treated cells were exposed to colcemid (0.04 µg/ml) for
25 minutes at 37°C and to hypotonic treatment (0.075 M KCl) for 20 minutes at room
temperature. Cells were fixed in a methanol and acetic acid (3:1 by volume) mixture for 15
minutes, and washed three times in the fixative. The slides were air-dried, stained in 4%
Giemsa and coded for the blind analysis. Later the slides were decoded for the evaluation
of results. Slides were analyzed for several parameters including chromosome aberrations
(as evidenced by both chromosome- and chromatid-type breaks), fragments, tetraploidy
and fusions. A total of 35 metaphases were analyzed from each sample. Each experiment
was conducted at least three times. Images were captured using a Nikon
80i microscope equipped with karyotyping software from Applied Spectral Imaging (ASI)
Inc., Vista, CA.
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2.2.14: DNA Fiber analysis
The DNA fiber spread technique is based on a protocol first published by Jackson and
Pombo, who used this assay to measure fork speed and origin firing in U2OS cells [170]. In
this assay, cells are labeled with the nucleoside analogs 5-Chloro-2′-deoxyuridine (CldU)
and 5-Iodo-2′-deoxyuridine [37], consecutively, for short time. CldU and IdU that get
incorporated in newly synthesized DNA mark the progression of replication forks. After
labelling, the cells are harvested, lysed in special buffer and the DNA is spread on glass
slides by tilting at an angle. The samples on glass slides are then fixed, blocked and stained
for immunofluorescence microscopy. Specific antibodies recognizing CldU and IdU and the
secondary antibodies coupled to fluorescent dyes allow for detection of labeled DNA tracks
on a confocal microscope. A schematic representation of resulting fork structures is shown
(Figure 17).
In our study, the DNA fiber analysis technique was employed to assess the origin
firings in UMSCC1 and HN31 cells under Chk1 inhibitor treatment. The cells were preincubated with DMSO or LY2606368 (5 nmol/L) for 90 minutes. After 90 minutes, the cells
were pulse-labelled with CldU (100 μM) for 30 min after which cells were quickly washed
with pre-warmed PBS for two times and incubated with IdU (150 μM) for 30 min. The
LY2606368 remained in the media throughout the labelling period. At the end of the
treatment, cells were washed with PBS, trypsinized. After trypsin neutralization, the cells
were re-suspended in PBS to a final density 1 X 10 6 cells/ml. 2.5 μL of cell suspension was
mixed with 7.5 μL of lysis buffer for 8 minutes, and cell lysis suspension was added as a
drop on a regular glass slide. The glass slide was tilted at an angle of 15 0 such that that the
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drop started running down and DNA spread over the slide. The slide was then air-dried,
fixed in methanol:acetic acid (3:1) at room temperature for 5 min. After washing twice with
PBS, the glass slide was incubated with 2.5N HCL at 370C in a humidified chamber.
The samples were blocked in 3% BSA in PBS for 30-40 minutes and thereafter
incubated with rat-anti CldU (1:150 dilution) and mouse anti-IdU (1:150 dilution) in 1% BSA
in PBS at 370C for 1hr. The samples were washed three times with PBS plus 0.1 % Triton X.
100 μL of secondary antibodies anti-rat Alexa 488 (1:150) and anti-mouse Alexa568
(1:200) diluted in the same blocking buffer were applied to the slide for 1 hr at 37 0C in a
humidified chamber. The samples were mounted for microscopy. Under each condition,
multiple images were captured. The total number of images that were captured under
each treatment cumulatively contained over 400 fiber spreads. The spreads were analyzed
for different replication structures and percentage 1st and 2nd label origin firings were
measured. Sidak’s multiple comparison tests was used to assess statistically significant
differences in between the groups [14].
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Figure 17: Replication structures seen after serial label with CldU and IdU
The CldU label is detected with green antibody and IdU label is detected with red antibody.
The origin quantification is done by counting total number origin firings under 1 st and 2nd
label as percent of total replication structures.
2.2.15: Statistical Analysis
Data for analysis were pooled from three independent experiments and each
experiment was carried out in triplicates. For clonogenic survival assays, data were
transformed with the square root function to correct for deviations from normality and
analyzed for statistical differences by conducting an ANOVA test, followed by the
Bonferroni multiple comparison test using GraphPad Prism version 6 software. Two-tailed
Student t tests were conducted for senescence and other unpaired group comparisons,
also using GraphPad Prism. Sidaks multiple comparison test was used for DNA fiber
analysis. For all comparisons, P < 0.05 was considered statistically significant [14].
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CHAPTER 3: RESULTS 1
This chapter is based on my own research work published last year in Molecular
Cancer Therapeutics (Mol Cancer Ther. 2013 Sep; 12(9):1860-73; PMID:23839309) titled
“Chk1/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells
secondary to the loss of functional p53”. As per the AACR policy posted on the website
(http://www.aacrjournals.org/site/InstrAuthors/ifora.xhtml#reuseauthors), the authors of
research articles published in AACR journals are permitted to use their article or parts of
their article (including figures and tables) in their thesis or dissertation without
requesting permission from the AACR.

3.1 Study rationale and scope
Although cisplatin is a widely used chemotherapy of choice for treating HNSCC
patients, only a subset of these patients respond favorably, while a significant number
have treatment refractory tumors [98, 171]. Therapeutic advancements in HNSCC have
been hindered due to an absence of reliable markers that predict cisplatin response [172].
In a recently performed whole exome sequencing of HNSCC tumors, we and others have
confirmed TP53 to be the most frequently altered gene in primary HNSCC tumors, thereby,
suggesting that it may serve as a potential biomarker for predicting therapeutic response
[36, 37]. Interestingly, mutation in p53 was shown to be associated with poor response to
therapy and decreased survival in HNSCC by several studies and the presence of wtp53 was
shown to predict for better therapeutic response and improved survival [173-175].
Unfavorable therapy outcome and bad prognosis in p53 mutant HNSCC tumors suggests

74

that p53 dependent response mechanism(s) following cisplatin treatment are altered in
p53 mutant HNSCC.
A number of in vitro studies investigating the role of p53 as a mediator of
chemosensitivity have produced contrasting results [91, 94, 176, 177]. Moreover, in a
variety of cell types, activation of p53 and induction of apoptosis was reported to be the
mechanism underlying the cytotoxic effect of cisplatin [47, 58, 178]. Studies with HNSCC
cells have also reached a similar conclusion [171, 179]. However, all of these studies were
conducted using cisplatin doses that were 10-50 fold higher than the clinically achievable
dose of cisplatin. Hence, it is currently unknown what mode of cell death is really
contributing to treatment responses when clinically relevant doses of cisplatin are used.
Interestingly, genotoxic stresses may also result in alternative cellular fates such as –
senescence, which is characterized by a non-proliferative state, or mitotic catastrophe,
which is characterized by the presence of giant multi-nucleated cells [58, 59]. Nonetheless,
the role of p53 in mediating cisplatin therapy response in HNSCC cells still remains
unanswered.
Cells that are proficient in p53, respond to DNA damage through p53 stabilization,
which then triggers cell cycle arrest and initiates DNA repair. In the absence of p53
function, however, important cellular responses like cell cycle arrest and DNA repair hinge
on the function of Chk1 and Chk2. Because therapeutic exploitation of the loss of TP53
tumor suppressor function has proven difficult for cancer treatment, we hypothesized that
a synthetic lethal strategy involving targeted inhibition of Chk 1/2 could be exploited for
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therapeutic benefit in p53 mutant HNSCC. Many studies have demonstrated that the
therapeutic effect of genotoxic agents could be enhanced by inhibiting DNA repair
enzymes such as the checkpoint kinases (Chk), especially in TP53 deficient cancers. Truly, a
number of human clinical trials have been initiated and are still in progress to evaluate the
efficacy of Chk inhibitors in combination with various chemotherapeutic agents. As these
investigational trials are still advancing in early stages, critical questions remain regarding
in which types of cancers this therapeutic strategy would be of benefit, whether the TP53
mutational status of tumors should be considered in patient selection criteria, and which
chemotherapies are effective with Chk inhibitors. There are presently no clinical trials or
preclinical studies investigating Chk inhibitors in combination with chemotherapeutic
agents specifically in HNSCC, and there is a dearth of studies examining the utility of Chk
inhibitors to sensitize cells to treatment with cisplatin, the front line chemotherapy for
treatment of aggressive HNSCC.
Enhancement in cisplatin toxicity upon inhibition of Chk has been reported by a few
studies in other cancer models; however, contrasting results have been seen in studies that
have found no therapeutic benefit with this combination treatment [180-184].
Nevertheless, whether the addition of Chk inhibitor would improve the cisplatin-induced
killing of p53 deficient HNSCC cells remains unclear. In the current study, we first
hypothesized that HNSCC cells respond to cisplatin in a p53 dependent manner and found
it to be true after testing this hypothesis using isogenic pair of HNSCC cell lines differing in
p53 status. Next, we show that the primary response of HNSCC cells harboring wtp53 to
cisplatin treatment is senescence rather than apoptosis and HNSCC cells that are deficient
76

in p53 function due to its loss or mutation fail to mount a senescence response. Finally, we
propose a strategy of inducing alternative cell death mechanism in p53 mutant or deficient
cells which evade senescence, by treating them with a Chk inhibitor that leads to mitotic
catastrophe.

Aim 1.1: To determine the clonogenic survival of HNSCC cells differing in p53
status in response to cisplatin
3.2 HNSCC cells respond to cisplatin in p53 dependent manner
We performed cisplatin titration on an isogenic pair of HNSCC lines originally derived
from the same patient that differ in the p53 status, namely HN30 (wtp53) and HN31, which
bears mutant p53 (mutp53; C176F and A161S), as well as an additional wtp53 cell line
(UMSCC17A) and assessed their colony formation ability using a standard clonogenic assay
(Figure 18). For UMSCC17A and HN30 cells (both wtp53), the IC50 of cisplatin was found to
be 0.16 μmol/L and 0.14 μmol/L, respectively, and for HN31 cells (mutp53) the cisplatin
IC50 was found to be 0.60 μmol/L.
Next, we sought to ascertain the relationship between functional p53 and cisplatin
sensitivity by performing cisplatin titration on wtp53-expressing HN30L [i.e., HN30 cells
infected with a lentiviral devoid of short hairpinRNA (shRNA)] and a derivative of the wildtype cell line referred to as HN30-shp53 in which p53 has been stably knocked down
following infection with an shRNA lentivirus, in a clonogenic assay. Strikingly, the cisplatin
IC50 for HN30L cells (IC50 = 0.12 μmol/L) was found to be 2.6 fold lower than HN30-shp53
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cells (IC50 0.32 μmol/L) which lend support to our hypothesis that cisplatin sensitivity in
HNSCC cells is p53-dependent (Figure 19). Representative images of differential response
to cisplatin treatment HN30, HN30-shp53, and HN31 cells are shown (Figure 20). The
remaining study was performed using parental HN30 cells as the cisplatin sensitivity of
HN30L and HN30 cells was found to be similar.

Figure 18

Figure 19
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Figure 20: HNSCC cells respond to cisplatin in p53 dependent manner
Figure 18, HN30, UMSCC17A (wtp53), and HN31 (mutp53) cells seeded for clonogenic
assay were treated with cisplatin for 24 hours and surviving colonies were counted after
imaging. (Figure 19), HN30L (wtp53) and HN30-shp53 (p53 knockdown) cells seeded for
clonogenic assay were treated with cisplatin for 24 hours at various concentrations (inset
western blot shows confirmation of p53 knockdown in HN30-shp53 cells). After drug wash
out, colonies were allowed to form and counted. Surviving colonies at each cisplatin
concentration were normalized to the control and plotted in the graphs. All cisplatin
treatments were carried out in triplicate and each experiment was repeated at least three
times. Note, in some cases error bars are not visible because they are smaller than marker
symbols. (Figures 20), the images shown are representative of differential response to
cisplatin observed in HN30, HN30-shp53, and HN31 cells.
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Aim 1.2: To investigate the prominent mode of cell death in response to
cisplatin in wtp53 HNSCC cells.
3.3: Senescence, but not apoptosis, is the major cellular response of wild type p53 HNSCC
cells in response to cisplatin
The cytotoxic effect of cisplatin has been ascribed to the activation of p53 and
induction of apoptosis in a variety of cell types [47, 58, 178]. Studies using HNSCC cells
have also reached a similar conclusion [171, 179]. However, all of these studies were
conducted using cisplatin doses that were 10-50 folds higher than the clinically achievable
dose of cisplatin. Hence, it is currently unknown what mode of cell death is really
contributing to treatment responses when clinically relevant doses of cisplatin are used.
So, we sought to investigate the prominent cellular outcome of wtp53 HNSCC cells at a
clinically achievable dose of cisplatin. Using cues from the literature about the likely
mechanism of death upon cisplatin treatment, we assayed HNSCC cells for apoptosis
induction using three complementary assays.
First, we performed a PI-based cell-cycle analysis on HNSCC cells and assessed the
sub-G1 values. Despite their differences in cisplatin sensitivity, the percentage sub-G1
values did not differ much from each other for HN30 and HN30-shp53, and they were
found to be less than 10% at all the time points (Figure 21). Next, using western blotting,
we probed for the presence of molecular marker for apoptosis, cleaved PARP, from the cell
lysates obtained from HN30, HN30-shp53, and HN31 cells at 24 and 48 hours post cisplatin
treatment. Cell lysates obtained from staurosporine (1 µmol/L) treated HN31 and HN3080

shp53 cells served as a positive control for apoptosis. At both the time points, none of the
cell types showed PARP cleavage post cisplatin treatment (Figure 22). These results
suggested that apoptosis was unlikely the prominent mode of cell death in response to
cisplatin treatment in these HNSCC cells.
Finally, to confirm that there was no significant apoptotic induction in HNSCC cells
post cisplatin treatment, we performed a morphological assessment of apoptotic induction
on cisplatin-treated HNSCC cells. The typical morphological characteristics that accompany
apoptosis such as membrane blebbing and nuclear fragmentation were absent in cisplatin
treated HN30 and HN30-shp53 cells (Figure 23). Moreover, we failed to detect TUNEL
(terminal deoxynucleotidyl transferase–mediated dUTP nick end labeling) positivity
indicating no apoptosis in HN30 cells after cisplatin treatment (Figure 24). Collectively,
these results led us to conclude that wtp53 HN30, its p53-deficient derivative HN30-shp53,
and p53-mutant isogenic variant HN31 undergo minimal apoptosis in response to cisplatin
treatment. For all the above experiments, we employed a clinically relevant dose of
cisplatin (1.5 μmol/L) at which no apoptosis could be detected. However, treatment of
HN30 cells with cisplatin at a high dose (20 μmol/L) induced PARP cleavage and we also
observed an increase in sub-G1 values, which indicated that apoptosis could be triggered in
HN30 cells when they are exposed to high doses of cisplatin (Figure 25).
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Figure 21
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Figure 22

Figure 23
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Figure 24: Apoptosis is not likely the main mode of cell death in HNSCC cells
Figure 21, HN30 and HN30-shp53cells were treated with cisplatin (Cisp) for 24 hours. At 24,
48, and 72 hours, cells were fixed and stained with PI and sub-G1 values were quantitated
by flow cytometry. Figure22, HN30, HN30-shp53,and HN31 cells were treated with
cisplatin (1.5 μmol/L) and cell lysates were collected at 24 and 48 hours post treatment.,
Lysates from staurosporine-treated (1 μmol/L) HN30, HN31, and HN30-shp53 cells were
collected at 8 hours and used as positive controls for apoptosis. Figure 23, HN30 and
HN30-shp53 cells were treated with cisplatin (1.5 μmol/L) for 24 hours. Later, cells were
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fixed, stained, and counter stained with DAPI and FITC–phalloidin, respectively.
Staurosporine (1 µmol/L)-treated HN30-shp53 cells were used a positive control (Con) for
apoptosis. HN30 cells were treated with 1.5 μM cisplatin for 24hrs. Figure 24, for apoptosis
detection at indicated time points, cells were first fixed in methanol free formaldehyde,
washed in PBS, permeabilized, and then processed as per the manufacturer’s instructions.
Cell nuclei were stained with DAPI and representative images were taken using spinning
disk confocal microscopy. DNase treated HN30 cells were used as a positive control for
apoptosis detection. All experiments above were repeated at least three times.
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Figure 25: Cisplatin induces apoptosis in HNSCC cells only at higher doses
HN30 cells were treated with cisplatin (20 µmol/L) for 24 hours and at given time points
cells were processed for flow cytometry and sub-G1 values were quantitated as earlier.
HN30 cells were treated with cisplatin (20 µmol/L) for 24 hours. After drug wash out, cell
lysates were collected at 30 hours and Western blot analysis was conducted to probe for
PARP cleavage (n=3).
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It was noted that wtp53 HN30, but not HN30-shp53, underwent a marked
morphological change upon cisplatin treatment. Treated cells revealed a flattened,
enlarged cell morphology reminiscent of senescence (Figure 26). Interestingly, genotoxic
stresses have been shown to culminate in alternative cellular fates such as – senescence,
which is characterized by a non-proliferative state, or mitotic catastrophe, which is
characterized by the presence of giant multi-nucleated cells [59, 60, 64]. Thus, we next
hypothesized that the reduction in colonies following cisplatin treatment in HN30 could be
due to induction of senescence. Four days post cisplatin treatment (1.5 μmol/L), HN30 and
UMSCC17A (wtp53) cells, were assayed for expression of SA-β-Gal, a hallmark of
senescence. We detected high levels of senescent cells (30%–60%) in cisplatin treated
UMSCC17A and HN30 cells Figure 27 and Figure 28. In contrast, a profoundly reduced
number of SA-β-Gal–staining cells (i.e., <5%) was seen in p53-knockdown HN30-shp53 cells
compared with HN30 cells (P < 0.01) and HN31 cells showed less than 10% senescent
positivity after cisplatin treatment Figure 28. In addition, protein lysates obtained from
cisplatin-treated HN30 and HN30-shp53 cells were probed for the presence of p21, a p53regulated mediator of senescence, using western blotting. p21 was found to be highly
induced in cisplatin-treated HN30 cells, but no induction of p21 was seen in cisplatintreated HN30-shp53 cells Figure 29.
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Figure 26

Figure 27
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Figure 28
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Figure 29 HNSCC cells undergo senescence in response to cisplatin (Cisp) treatment in a
p53-dependent manner
Figure 26, HN30 and HN30-shp53 cells were treated with cisplatin for 24 hours and
visualized by light microcopy 4 days later (x20 magnification). Figure 27, HN30, UMSCC17A,
and HN30-shp53 cells were treated with cisplatin (1.5 µmol/L) for 24 hours, and 4 days
later, cells were assayed for β-Gal enzymatic activity. The β-Gal senescent staining
observed in HN30 and UMSCC17A cells is illustrated in the photos (x10magnification).
Figure 28, the proportion of β-Gal–positive cells in HN30, UMSCC17A, and HN30-shp53
cells were graphed. Similarly, HN31 cells treated with cisplatin were assessed for β-Gal
staining. Figure 29, cell lysates from cisplatin-treated HN30 and HN30-shp53 cells were
probed for the presence of p21 using Western blot analysis. For all experiments, n=3.§,
Significantly different from cisplatin treated HN30 cells by two-tailed Student t test
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Aim 1.2.1: To determine whether the cisplatin induced senescence in wtp53 HNSCC cells
is dependent on p21
We created a stable lentiviral knockdown of p21 in HN30 cells (HN30-shp21 cells),
and subsequently assayed for senescence post cisplatin treatment. A complete loss of the
basal levels of senescence in HN30L upon p21 knockdown (HN30-shp21 cells) was evident,
and we detected a significantly lower number of senescent cells (<20%) in HN30- shp21
cells (P < 0.0001) post cisplatin treatment (Figure 30). Collectively, the above findings
suggest that senescence, not apoptosis, is the main cellular outcome in wtp53 HNSCC cells
in response to cisplatin and p21 is critical for the cisplatin-induced senescence in wtp53
HNSCC cells.
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Figure 30 Senescence induction in wild type p53 HNSCC cells is mediated by p21
Representative photos of cisplatin-treated HN30L and HN30-shp21 cells were taken after
β-Gal staining (x20 magnification) and the percentage of β-Gal–positive cells was graphed.
Western blot analysis was conducted to confirm knockdown of p21. For all experiments,
n=3. ‡, significantly different from cisplatin-treated HN30L cells by two-tailed Student t
test. Con, control.
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Aim 1.3: To determine the clonogenic survival of HNSCC cells (wt, null and
mut p53 background) in response to cisplatin plus Chk1/2 inhibitor
treatment
3.4: p53 deficient or mutated HNSCC cells are sensitized to cisplatin through inhibition of
Chk1/2 kinases
Resistance to cisplatin-induced senescence most likely accounts for the reduced
sensitivity to cisplatin in HN31 cells which harbor mutp53. An overwhelming majority of
HNSCC patients tumors harbor mutation in TP53 gene and thus as a prelude to improving
outcomes for those with this disease, we hypothesized that cisplatin-resistant HNSCC
lacking wtp53 could be rendered more sensitive through alternative death mechanism. To
test this hypothesis, we evaluated whether cisplatin-resistant HNSCC cells containing
mutp53 could be directed toward mitotic catastrophe.
Cancer cells expressing wtp53, respond to DNA damage through p53 stabilization,
which leads to transcription of p21 and other genes that can then trigger cell cycle arrest
and initiate DNA repair. In the absence of p53 function, however, the important cellular
responses like cell cycle arrest and DNA repair hinge on the function of Chk1 and Chk2.
Thus, we hypothesized that p53-mutant HNSCC cells could be sensitized to cisplatininduced cell death through inhibition of Chk1/2 kinases. To test this hypothesis, we treated
HN31 (mutp53) and HN30 (wtp53) cells with cisplatin at two different doses and in
combination with AZD7762, a pan Chk1/2 inhibitor, and the colony formation ability was
assessed in a clonogenic assay. The combination treatment led to a significant reduction in
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number of colonies than seen with cisplatin or AZD7762 treatment alone in HN31 cells (P
<0.003), at both the concentrations of cisplatin (Figure 31). In contrast, only a marginal
increase in colony reduction above single-agent treatment with cisplatin was observed
with the combination treatment in HN30 cells (P > 0.999) (Figure 32). The combination
treatment was found to be significantly more effective than AZD7762 or cisplatin
treatment alone in HN30-shp53 (p53-knockdown cells) (P < 0.0003) (Figure 33). These data
indicate that the addition of Chk inhibitor may enable in overcoming the cisplatin
resistance of p53 mutant or null HNSCC cells.
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Figure 31: Inhibition of Chk1/2 sensitizes p53-mutant HNSCC cells to cisplatin (Cisp)
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Figure 32: Inhibition of Chk1/2 sensitizes p53 knockdown HNSCC cells to cisplatin (Cisp)
Figure 31, HN30 and HN31 cells were seeded for clonogenic assay and subjected to
following treatments: DMSO (CNT), AZD7762 alone (100 nmol/L for 48 hours), cisplatin (0.4
and 0.8 µmol/L; 24 hours), and cisplatin plus AZD7762 (combination for 24 hours, then PBS
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wash, AZD7762 treatment for another 24 hours). Treatments were carried out in triplicate
wells. Later, surviving colonies were stained and counted as described previously. Surviving
colonies in each treatment were normalized to the control (Con) and the data plotted.
Figure 32, the clonogenic survival of HN30L (empty lentiviral control) and HN30-shp53 cells
in response to the individual treatments was determined and surviving colonies were
counted and plotted. For all experiments, n =3.*, Significantly different from single-agent
cisplatin or AZD7762 treatment in the same group using one-way ANOVA and Bonferroni
multiple comparison test.

Sub Aim 1.3.1: To evaluate the effect of cisplatin treatment on the clonogenic survival of
p53 mutant HNSCC cells upon siRNA knockdown of Chk1/2 kinases
In order to confirm the findings that cisplatin sensitization of p53-mutant HNSCC cells
is specifically due to inhibition of Chk kinases, we performed siRNA knockdown of Chk1,
Chk2, or both in HN31 cells. The Chk knockdown cells seeded for clonogenic assay were
then exposed to two doses of cisplatin for 24 hours and the colony forming ability was
assessed. The knockdown of Chk1 and Chk2 was confirmed using western blot (Figure 33).
The cisplatin responses observed in HN31 mock-treated or transfected with control
scrambled siRNA-transfected were similar to each other, suggesting no real effects from
the control siRNA knockdown (Figure 34). Overall, at both doses of cisplatin, the
knockdown of Chk1 or Chk2 alone lowered the clonogenic survival compared with
scramble. However, a statistically significant difference was observed only at lower dose of
cisplatin in Chk2 knockdown alone cells (P < 0.0001). At lower dose of cisplatin, the Chk2
knockdown resulted in greater colony killing than the Chk1 knockdown (P < 0.0001). At
higher dose of cisplatin, a significant reduction in the survival was observed with double
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knockdown compared with scramble suggesting that Chk1 knockdown improved the
results over Chk2 knockdown alone (P < 0.0001).

Figure 33: Western blot showing siRNA knockdown of Chk1 and Chk2 in HN31 cells
HN31 cells were electroporated with buffer alone (mock), control scrambled siRNA, Chk1
siRNA, Chk2 siRNA, or Chk1/Chk2 siRNA, and then seeded for western blot Twenty-four
hours after electroporation with different siRNAs, HN31 cells were treated with cisplatin
(1.5 μmol/L) and cell lysates were collected 24 hours later. The knockdown of target genes
was confirmed by Western blot analysis. For all experiments, n=3.
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Figure 34: Knockdown of Chk1/2 sensitizes p53 mutant HN31 cells to cisplatin
Mutant p53 expressing, HN31 cells were electroporated with buffer alone (mock), control
scrambled siRNA, Chk1 siRNA, Chk2 siRNA, or Chk1/Chk2 siRNA, and then seeded for
clonogenic assay. Twenty-four hours post electroporation, cells seeded for clonogenic
assay were treated with cisplatin (0.4 and 0.8 μmol/L; 24 hours). After drug wash out,
colonies were allowed to form, stained, and counted as described earlier. For all
experiments, n=3. †, Significantly lower than scramble-transfected cells treated with
cisplatin (0.4 μmol/L); ‡, significantly lower than Chk1 knockdown cells treated with
cisplatin (0.4 μmol/L); §, significantly lower than scramble-transfected cells treated with
cisplatin (0.8 μmol/L), using one-way ANOVA and Bonferroni multiple comparison test
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Aim 1.4: To identify potential molecular alterations in the DDR pathway of
HNSCC cells after cisplatin plus Chk1/2 inhibitor treatment
3.5: Cisplatin plus Chk1/2 inhibitor treatment induces robust activation of DNA damage
response pathways in p53 deficient HNSCC cells
First, we verified the ability of AZD7762 to inhibit Chk activity by conducting Western
blot analysis on HN31 cells treated with cisplatin or cisplatin plus AZD7762. Chk1
phosphorylation on S296 site was analyzed as a read out of Chk1 activity. Chk1 pS296
levels were detectable after 24 hours of cisplatin treatment and for an additional 24 hours
following washout of the drug. As expected, AZD7762 treatment significantly reduced the
cisplatin-induced phosphorylation of Chk1 on S296 at both time points, indicating that the
inhibitor was acting on its intended target (Figure 35).
The molecular alterations triggered due to cisplatin, AZD7762, or their combination
was analyzed by western blotting (Figure 36). Compared with DMSO or no treatment, we
observed an increase in phospho-Chk1 (S345) levels with cisplatin treatment for all three
cell lines and these levels were enhanced following the combination therapy in most cases.
AZD7762 treatment alone also led to increases in Chk1 pS345 levels in 2 of 3 cell lines,
which is suggestive of a regulatory feedback response in cells where the Chk activity was
diminished by drug. The Chk1 S345 phosphorylation is thought to be mediated by
upstream kinases such as the ataxia telangiectasia related (ATR) protein which facilitates
auto phosphorylation on S296 during Chk1 activation. Increase in the levels of phosphoH2AX (i.e., ϒ-H2AX), a DNA damage marker, was observed following cisplatin treatment in
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all three cell lines. The combination of cisplatin plus AZD7762 led to a further elevation in
ϒ-H2AX levels which is likely a result of enhancement in DNA damage. The increase in ϒH2AX was also accompanied by increase in Chk2 phosphorylation on Thr68 following
combination therapy, which was found to be enhanced in mutp53 HN31 cells and in the
p53-knockdown HN30-shp53 cells. Cisplatin treatment also led to a phosphorylation on
p53 at S15 site in HN30 and HN31 cells and these levels were moderately enhanced
following the combination treatment. However, we failed to detect accumulation of total
p53 with either cisplatin or the combination treatment. As expected, cisplatin treatment
induced p21 in HN30 cells. A similar level of p21 induction was also observed in HN30 cells
following the combination treatment. In HN31 and HN30-shp53 cells, however, the p21
levels were barely detectable under all the treatment conditions.
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Figure 35: AZD7762 inhibits Chk1 kinase phosphorylation on S296 site in HN31 cells
The effect of each individual treatment on the Chk1 phosphorylation at S296 site was
assessed by western blot.
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Figure 36: Assessment of molecular changes in DDR pathway in HNSCC cells differing in
p53 status
Cell lysates from HN31, HN30, and HN30-shp53 cells under individual treatments were
collected at 24 hours and the levels of DNA damage response markers and also the levels
of phospho-H3 (S10), a mitotic marker were examined by Western blot analysis. p21 levels
were examined from cell lysates collected at 72 hours. For all experiments, n=3.
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Aim 1.5: To investigate cell death response in p53 mutated or deficient
HNSCC cells after cisplatin plus Chk1/2 inhibitor treatment
3.6: p53 mutated or deficient HNSCC cells undergo mitotic cell death following cisplatin
plus Chk1/2 inhibitor treatment
Abrogation of the G2/M checkpoint leads to an early M phase entry and a modified
mitosis program which results in generation of polyploid cells. Since Chk1/2 kinases are
critical enforcers of G2/M checkpoints, we first investigated whether our individual drug
treatments led to polyploidy in HN30, HN30-shp53, or HN31 cells by performing cell-cycle
analysis to measure %8N or polyploidy values at various times post treatment. In HN30,
HN31, and HN30-shp53 cells, at earlier time points (i.e., 24 and 48 hours), we observed
that combination treatment induced negligible polyploidy over the cisplatin treatment
alone (P > 0.700) (Figure 37). However, at 72 hours, the 8N values were significantly
increased with the combination treatment in HN30, HN31, and HN30-shp53 cells compared
with cisplatin treatment alone (P < 0.0001). Importantly, significantly higher levels of
polyploidy induction were observed with the combination treatment in HN31 and HN30shp53 cells compared with HN30 cells (P <0.0001), with absolute 8N values that were at
least double to that observed in HN30 cells at the 72-hour time point. Thus, cisplatin plus
Chk inhibitor induced significant polyploidy in HN31 and HN30-shp53 cells.
Next, we performed immunofluorescence microscopy following combination
treatment in HN31 and HN30-shp53 cells to assess for the presence of multinucleated cells,
also a characteristic of mitotic catastrophe. Indeed, the combination treatment led to
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generation of multinucleated cells in HN31 and HN30-shp53 cells, that were not apparent
after exposure to cisplatin or AZD7762 alone, (Figure 38). A percentage quantification of
multinucleated cells observed under each treatment is shown (Figure 39). The induction of
polyploidy and the appearance of multinucleated cells in p53-deficient HNSCC cells after
combination treatment suggested that the cells were undergoing mitotic catastrophe.
Next, we assessed the levels of the mitotic marker protein, phospho – H3 in p53
proficient and deficient HNSCC cells under individual treatment conditions. In wtp53 HN30
cells, we observed that cisplatin treatment led to reduction in levels of the mitotic marker
protein phopho-H3, which suggested of a drop in the number of cells undergoing mitosis
(Figure 36). Furthermore, these levels were not restored upon addition of AZD7762. A
decrease in phosho-H3 levels was also observed in HN31 and HN30-shp53 cells after
exposure to cisplatin. However, the addition of the Chk inhibitor to cisplatin prevented the
drop in phospho-H3 which suggests that Chk1/2 inhibition led to abrogation of cisplatin
induced checkpoint arrest. The checkpoint abrogation due to inhibition of Chk1/2 kinases
resulted in unscheduled mitosis, which is also evident from the increase in phospho-H3
(S10) levels (Figure 36). Cells that underwent such abrupt mitosis died via mitotic
catastrophe since accumulation of sub-G1 fraction at later time points was observed
(Figure 40). At 96 hours, the combination treatment induced significantly higher sub-G1
values over cisplatin treatment alone in HN31 and HN30-shp53 cells (P < 0.0015). On the
other hand, not much difference in the sub-G1 values was observed with the combination
or cisplatin treatment alone in HN30 cells at 96 hours (P > 0.05). Collectively, these results
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indicated that Chk inhibition led to an override of the cell cycle checkpoint in p53-deficient
HN31 and HN30-shp53 cells in response to cisplatin treatment.

.
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Figure 37: Cisplatin (Cisp) plus Chk inhibitor induces polyploidy in p53-mutant or knockdown HNSCC cells.
HN30, HN31, and HN30-shp53 cells were treated with DMSO(CNT), AZD7762 alone (Chk
100 nmol/L), cisplatin (1.5 μmol/L), or cisplatin plus AZD7762 (Cisp plus Chk). The duration
of individual treatments was similar to that in clonogenic assays. Cells were collected at 24,
48, and 72 hours, fixed, stained with PI, and FACScan analysis was conducted to determine
%8N or polyploidy values. Each cell-cycle experiment was carried out at least two times. In
some cases, error bars may not be visible because they are smaller than marker symbols. †,
Significantly greater than cisplatin treatment alone in each group; *, significantly greater
than the combination treatment in HN30 cells at 72 hours time point, using one-way
ANOVA and Bonferroni multiple comparison test.
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Figure 38: Cisplatin (Cisp) plus Chk inhibitor treatment leads to the generation of
multinucleated cells in p53-mutant or - knockdown HNSCC cells
HN31and HN30-shp53 cells were subjected to individual treatments as described earlier. At
four days post treatment, cells were fixed, stained with DAPI, and counterstained with
FITC–phalloidin. Light fluorescence microscopy was conducted and representative images
under each treatment were taken. Red arrows show multinucleated cells Experiments
were repeated at least three times.
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Figure 39: Cisplatin (Cisp) plus Chk inhibitor treatment lead to generation of
multinucleated cells in p53-mutant or - knockdown HNSCC cells
Percentage of multinucleated cells under each treatment condition is plotted on graph.*,
significantly greater than cisplatin treatment alone using two-tailed Student t test (n=3).
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Figure 40: Quantification of subG1 values under various treatment conditions in HN31,
HN30-shp53 and HN30 cells
HN31 and HN30-shp53 cells were exposed to individual treatments as described earlier
and harvested at 24, 48, 72, and 96 hours, and sub-G1 values were quantitated using flow
cytometry. (n=3). ‡, Significantly greater than cisplatin treatment alone in each group using
two-tailed Student t test. Con, control.
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Aim 1.6: To investigate the effect of cisplatin plus Chk1/2 inhibitor
treatment on HNSCC cells harboring different p53 mutations
3.7: Addition of Chk1/2 inhibitor to cisplatin sensitizes HNSCC cells harboring different
p53 mutations
Given that a spectrum of p53 mutations are seen in HNSCC patients, we wondered
whether HNSCC cells containing different p53 mutations would respond similarly to the
cisplatin plus Chk inhibitor combination treatment. SCC-61 and Cal27 cells harboring R110L
and H193L mutations, respectively, were seeded for clonogenic assay and exposed to the
individual treatments. A strong potentiation in the colony reduction was observed in both
SCC-61 and Cal-27 cells with combination treatment (P< 0.0001) over cisplatin or AZD7762
treatment alone indicating that sensitization to cisplatin induced by inhibiting Chk1/2
kinases occur in multiple p53-mutant HNSCC cells (Figure 41).
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Figure 41: HNSCC cells harboring different p53 mutations are also sensitive to cisplatin
(Cisp) plus Chk inhibitor treatment
SCC-61 (R110L) and Cal-27 (H193L) cells were seeded for clonogenic assay. Cells were then
exposed to the following treatments: DMSO (Con), AZD7762 alone (100 nmol/L for 48
hours), cisplatin (0.5 and 1 μmol/L; 24 hours), and cisplatin plus AZD7762 (combination for
24 hours, then PBS wash, AZD7762 treatment for another 24 hours). Each treatment was
carried out in triplicate. Surviving colonies in each treatment were counted, normalized to
the control (Con), and plotted on the graph as shown. Experiments were repeated at least
three times. *, Significantly different from single-agent cisplatin or AZD7762 treatment in
the same group using one-way ANOVA and Bonferroni multiple comparison test.
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CHAPTER 4: DISCUSSION
4.1: Cisplatin responses in HNSCC cells differing in p53 status
Although there have been considerable improvements in surgical techniques and
multimodality treatments for HNSCC, the survival outcomes have improved marginally over
the past forty years [176, 185]. Cisplatin is the mainstay chemotherapeutic agent in HNSCC,
but it is not that effective as a monotherapy. Variable responses to the cisplatin treatment
in HNSCC tumors have been attributed by several studies to the presence of drug
resistance mechanisms such as reduced drug uptake, increased drug detoxification
process, enhanced DNA repair, and suppressed apoptotic response, whereas others have
sought to link the cisplatin responses of HNSCC cells to the expression levels of certain
biomolecules thereby tagging them as potential biomarkers [47, 52, 91]. TP53, the tumor
suppressor gene, is one such biomolecule found to be altered through mutation in 60%80% of human papillomavirus (HPV)–negative HNSCC specimens [36]. Interestingly, studies
investigating relationship between p53 status and clinical responses in HNSCC patients
have found that patients harboring wtp53 had favorable therapeutic response and better
survival outcomes, whereas patients with mutp53 had poor therapeutic response and
decreased survival [173-175].
Here we sought to determine the impact of p53 function on the cisplatin responses of
HNSCC cells using an in vitro model system. We found that wtp53-bearing HNSCC cells,
HN30, were highly sensitive to cisplatin, and the loss of wtp53 expression through p53
stable knockdown in HN30 (HN30-shp53) conferred resistance to cisplatin. To eliminate the

117

possibility that the observed sensitization to cisplatin by wtp53 is limited to only one
genetic background, we performed a similar experiment with UMSCC17A cells (wtp53),
and consistent with our prediction, these cells were found highly sensitive to cisplatin.
Furthermore, because of the high prevalence of p53 mutation in HNSCC, we questioned
whether mutp53 HNSCC cells respond differently to cisplatin treatment. To answer this
question, we used HN31 cell line that harbored p53 mutation but was isogenic to wild-type
p53 bearing HN30 cell line. HN30 cell line was established from a primary tumor of HNSCC
patient, while HN31 was established from a lymph node metastatic site of the same patient
[186]. We found that mutation in p53 rendered HNSCC cells highly resistant to cisplatin.

4.2: Cellular outcomes in response to cisplatin in HNSCC cells
4.2.1: Apoptosis, not a major cellular outcome upon cisplatin treatment
Cisplatin is thought to exert its cytotoxic action primarily through induction of
apoptosis. However, in this study, regardless of the p53 status, we failed to find evidence
of apoptosis as the prominent response of HNSCC cells to cisplatin treatment. Firstly, we
could not detect cleaved PARP, a canonical marker of apoptosis, in response to cisplatin
treatment at either earlier or later time points in HNSCC cells. Next, the sub-G1 population
of HNSCC cells detected during cell cycle analysis was less than 10% at all these time
points, indicating minimal apoptotic induction in response to cisplatin. Moreover, cisplatintreated HNSCC cells failed to show TUNEL positivity or exhibit typical morphological
characteristics accompanying apoptosis such as membrane blebbing and nuclear
fragmentation.
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Contrary to our findings, several groups have shown that the cisplatin response in
cancer cells is mainly due to the induction of apoptosis. One explanation for the lack of
apoptotic detection in our assays could be the choice of time points. In our apoptotic
assays, we have not assessed cellular responses beyond 72 hrs time point, which leaves a
possibility that HNSCC cells may be undergoing apoptosis at later points. Another
explanation for this discrepancy between our results and those from other groups is the
concentration of cisplatin used in the study. Cisplatin is usually given as a bolus infusion to
HNSCC patients and it has an area under the curve [37] value of 3.98 mg.h/L [187]. For
cultured cells, this value translates to an equivalent in vitro cisplatin exposure of about 1
µmol/L over 24 hours or 24 µmol/L.h. The cisplatin exposures utilized by other research
groups in their study were 10 to 50-fold higher than the clinically relevant exposures of
cisplatin. Therefore it is likely that such high doses of cisplatin could elicit an apoptotic
response, however, this may not reflect the actual biological outcome of cisplatin
treatment in patients. In this study, we have employed clonogenic assay to ascertain
cellular responses to cisplatin, and for all remaining experiments we have used a
physiologically relevant dose of cisplatin (i.e., 1.5 µmol/L over 24 hours). Thus, we believe,
our results are more relevant to the clinical scenario in which HNSCC patients receive
treatment with cisplatin.
4.2.2: Senescence, a prominent cellular response to cisplatin in wtp53 HNSCC cells
In addition to apoptosis, senescence and mitotic catastrophe are the two alternative
cellular responses to cisplatin that have been previously reported in the literature [64].
Senescence manifests itself as a metabolically active but terminal non-proliferative cellular
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state. Cells undergoing senescence adopt enlarged flat, "pancake-like" cell morphology and
show an enhanced SA-β-Gal staining at pH 6. We had observed a striking change in the
morphological appearance of wtp53 HNSCC after cisplatin treatment. The cisplatin treated
wtp53HNSCCcells became large and displayed a "pancake-like" appearance that is
characteristic of senescence and, furthermore, a significant number of these cells stained
for the senescent marker β-galactosidase.
Although the SA-β-Gal activity is widely used to identify senescent cells, there are
some limitations to using this assay alone for senescence detection. It is known that culture
conditions such as serum starvation and increased cell confluence influence SA-β-Gal
activity [188]. Moreover, SA-β-Gal activity is proposed to be a surrogate marker for
increased lysosome number or activity [189]. Truly, enhancement of SA-β-Gal activity has
been reported by some studies in non-senescent cells. Thus, the detection SA-β-Gal activity
alone is clearly inadequate criteria to identify senescent cells.
In our study, in addition to SA-β-Gal activity detection, the presence of characteristic
morphological features that accompany senescence were also examined. Further support
to the senescent phenotype seen in wtp53 HNSCC cells came from the induction of p53regulated p21, a canonical upstream mediator of senescence. In contrast, none of the
senescent features were evident when p53 was either lost or mutated. In addition to
above findings, the data regarding HNSCC cellular responses to cisplatin were further
supported by parallel studies in our laboratory. An exogenous expression of wtp53 in p53null HNSCC cell lines (UMSCC1 and PCI13) were found to confer sensitivity to cisplatin, and
the cisplatin sensitivity in these cells was not an outcome of apoptosis but due to
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senescence induction via a p53–p21 axis (Osman; unpublished data). Collectively, these
data indicate that sensitivity to cisplatin is mediated by wtp53 and suggest that HNSCC
tumors bearing wild-type p53 primarily respond to cisplatin by senescence.

4.3: Improvement in cisplatin efficacy by Chk1/2 inhibition in p53 mutant or
deficient HNSCC cells via induction of mitotic catastrophe
The above results suggested that the cisplatin resistance observed in the mutp53 or
p53-knockdown setting is probably an outcome of failure to activate the senescence
program. To overcome the cisplatin resistance of mutp53 or p53 null HNSCC cells, we
investigated whether these cells are vulnerable to alternative forms of cell death. Chk1/2
kinases are well-recognized enforcers of S and G2–M cell-cycle checkpoints. In response to
DNA damage, they are rapidly activated to initiate cell-cycle arrest, DNA repair, and inhibit
cell death. Thus, Chk serves to complement the functions of wtp53 upon DNA damage
induction. When the p53 function is absent, due to its loss or mutation, Chk1/2 kinases
assumes the central charge of orchestrating these critical cellular functions. Consequently,
the relaxation of checkpoint functions has been shown to augment cytotoxicity of
genotoxic therapies in a variety of cell lines with defective p53 function [155, 156, 158].
Yet, the studies specifically examining the effect of addition of Chk inhibitor to cisplatin
have presented contrasting results. This inconsistency in results could probably be
attributed to different genetic backgrounds of culture cells or tumor types tested [183,
190]. Also, in some instances the p53 status was not considered for examining the efficacy
of the combinatorial regimen.
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Here, we provide evidence that targeted inhibition of Chk1/2 preferentially
sensitizes p53-knockdown or mutp53 HNSCC cells to cisplatin. The mechanism of
sensitization is through the abrogation of cell cycle checkpoints which results in overriding
of cisplatin induced cell-cycle arrest and culminates in forced mitosis. Consistent with the
mechanism, the combination treatment did not induce a drop in phospho-H3 levels in p53null or mutp53 settings. Higher levels of polyploidy or 8N values were detected in 18% to
20% p53-knockdown or mutp53 HNSCC cells following the combination treatment which
suggested that these cells underwent mitotic catastrophe. Mitotic catastrophe is a type of
post mitotic death which is characterized by formation of large nonviable cells with
multiple nuclei [64]. Although the combination treatment in wtp53 HNSCC cells also led to
an increase in the percentage of polyploidy, these values were considerably lower than in
the p53-null or mutp53 setting. This indicates that only a small fraction of wtp53 HNSCC
cells underwent mitotic catastrophe, possibly as a result of their slippage from checkpoint
arrest. The absence of higher polyploidy values in wtp53 HNSCC cells probably explains
why there was no significant increase in the sub-G1 values in these cells after the
combination treatment compared with cisplatin alone. Thus, combination treatment had
no apparent sensitization effect in wtp53 HNSCC cells. While the mutp53 or p53 null
HNSCC underwent mitotic catastrophe, these cells did not die through apoptosis as we
were unable to detect PARP cleavage under these treatments.
Several previous studies have reported preferential requirement of either Chk1 or
Chk2 for mediating resistance to radio- or other cytotoxic therapy [159, 191]. In contrast to
these studies, we report that both Chk1 and Chk2 contribute to cisplatin resistance in p53122

knockdown or mutp53 HNSCC cells. Nonetheless, our data suggest that Chk2 inhibition is
probably more important for sensitization of p53-knockdown or mutp53 HNSCC cells to
lower doses of cisplatin, and at higher dose of cisplatin the greatest sensitization is
effected through a double inhibition Chk1 and Chk2. Patients with HNSCC show a gamut of
p53 mutations that span across the 11 exons encoding the p53 protein. We investigated
whether the chk1/2 inhibition improves the cisplatin responses in HNSCC tumors bearing
different p53 mutations and show that the combination regimen is indeed effective in
HNSCC cell lines regardless of the type of p53 mutations.

4.4: Study limitations and Conclusions
By presenting compelling in-vitro evidence, we have offered a novel strategy to
overcome cisplatin resistance of p53 deficient HNSCC cells; however, follow-up studies
using in vivo mouse models must be conducted in the future to confirm the efficacy of our
treatment strategy. Chk inhibitors have been shown to sensitize tumor cells to genotoxic
therapies in both in vitro and in vivo models for other cancer types, thus lending us some
confidence that our results could be translated in in vivo setting [160]. Our data imply that
HNSCC cells carrying various p53 mutations are susceptible to the cisplatin plus chk
inhibitor combination treatment. However, only a subset of p53 mutations in HNSCC were
tested in this study, which opens a possibility that cells bearing untested p53 mutations,
may behave differently to the combination treatment. However, emerging data from our
lab support the findings of this study. Regardless of these limitations, we have presented
unambiguous evidence that HNSCC cells respond to cisplatin in a p53-dependent manner.
Next, we show that senescence, but not apoptosis is most prominent cellular outcome in
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HNSCC cells treated with cisplatin, and that relative resistance to cisplatin demonstrated by
p53-null or mutant HNSCC cells is likely due to their failure to initiate senescence
programs. Finally, we demonstrate one promising strategy to sensitize p53-null or mutp53
cells to cisplatin treatment. By performing this preclinical groundwork, we show that a
precision medicine approach may be feasible for the treatment of HNSCC based on Chk
inhibition in p53-mutant cells. Whether this approach will be useful for improving
treatment outcomes of patients with p53-mutant HNSCC needs to be determined by
further preclinical and clinical investigation.

124

CHAPTER 5: RESULTS 2
5.1 Study rationale and scope
A number of studies have focused on the DNA damage response (DDR) pathway to
identify molecular factors mediating resistance to genotoxic therapies [192]. In response to
cisplatin treatment, the DDR pathway rewires cell cycle machinery and initiates DNA repair
processes to aid cell survival and escape death [47]. Chk1/2 kinases that are centrally
placed in the DDR pathway mediate these cellular responses through induction of the S
and, G2/M DNA damage checkpoints[111]. Consequently, many groups have exploited
tumor cell dependency on the G2/M checkpoint following DNA damage via synthetic lethal
approach by targeted inhibition of Chk1/2 kinases [155, 192]. In the earlier chapters
(Chapter 3 and 4), we have demonstrated that the relative cisplatin resistance of p53
mutant HNSCC cells could be overcome by targeted inhibition of Chk1/2 kinases. This
enhancement in the in-vitro efficacy of cisplatin was shown to be due to abrogation of
G2/M checkpoint which results in mitotic catastrophe.
More recently, another important function of Chk1 kinase in a different phase of cell
cycle has come to fore. In an unperturbed cell cycle, Chk1 kinase serves to ensure proper
DNA replication and maintain genomic integrity through suppression of origin firings and
promotion of replication fork stability [138, 139]. This function of Chk1 kinase becomes
uniquely important for cancer cells because they enter S phase more frequently than the
normal cells. Frequent entry into the cell cycle requires uninterrupted supply of nucleotide
precursors and coordinate action of various cell cycle proteins to ensure proper DNA
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synthesis. However, interruptions in these processes are not uncommon in tumor cells,
which make the extremely complex task of DNA replication even more challenging. As a
result of this, cancer cells are confronted with replication stress. To escape catastrophic
consequences of replication stress, tumor cells become addicted to pathways that alleviate
replication stress and/or promote cell survival. The ATR-Chk1 pathway is a key signaling
pathway that aids cancer cell survival under conditions of replication stress [140, 141, 143].
Consequently, exploiting tumor cell dependency on this pathway through targeted
inhibition of Chk1 or ATR is currently being evaluated as a novel therapeutic strategy in
cancer cells [193, 194].
Inhibition of Chk1 kinase alone has been reported to induce DNA breaks, initiate
premature origin firings, delay fork progression and loss of cell viability in at least one
cancer cell line [138]. Contrary to these results, other studies have reported that Chk1
depletion or inhibition has no effect on cell viability in a variety of cancer cells [195-199].
Furthermore, groups using different in-vitro cellular models have proposed that Chk1
kinase becomes essential in the S phase and critical for cell viability only when replication is
challenged [200-204]. While the above studies indicate that Chk1 function may be cell
context dependent, it is presently not known whether Chk1 kinase plays an essential role in
HNSCC cells. Moreover, it is also not known whether Chk1 inhibition would elicit similar
biological responses across HNSCC cells derived from different tumor backgrounds.
In our current study, we screened 49 HNSCC cell lines for their sensitivity to two
different Chk kinase inhibitors, LY2606368 (Chk1 inhibitor) and AZD7762 (Chk1/2 inhibitor),
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and found out that 9 out of 49 cell lines (roughly 20%) of HNSCC cells are acutely sensitive
to these inhibitors alone. Next, we report that Chk1, but not Chk2, mediates cell survival in
the Chk inhibitor sensitive (hereafter, Chk sensitive,) HNSCC cells, and that Chk1 kinase
inhibition induces characteristic early S phase arrest, DNA breaks, and aberrant increase in
origin firings ultimately leading to loss of cell viability in these cells. Molecular response
characterization in these sensitive cells showed striking elevation in gammaH2AX, pATM
(S1981), and pRPA (S32), and pHSP27 (S82) upon Chk1 inhibition. All these molecular
changes were not observed in Chk-inhibitor-resistant cells. Furthermore, we show that
depletion of cdk2, not cdk1 prevents the phenotypic occurrences upon Chk1 inhibition in
the sensitive cells.

Aim 1.1: To determine the effect of two Chk kinase inhibitors AZD7762 and
LY2606368 on the cell viability of 49 HNSCC cell lines
5.2: A significant subset of HNSCC cell lines is acutely sensitive to Chk1 kinase inhibition
A phosphoproteomic analysis that was previously performed by our group on tumor
specimens from treatment naïve HNSCC patients matched with their normal mucosa had
identified checkpoint kinases (pChk1 serine 345 (S345) and pChk2 S33/35 as the most
significantly elevated phosphoproteins [205]. Thus, we initiated a program to investigate
whether Chk inhibition potentiates the colony killing induced by cisplatin in a panel of
HNSCC cell lines. During the course of this screening, we serendipitously found that certain
HNSCC cell lines were acutely sensitive to single agent Chk inhibitor (Figure 42 and Figure
43) which led us to hypothesize that a significant subset of HNSCC cell lines are exquisitely
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sensitive to Chk kinase inhibition. To examine our hypothesis, we performed a sensitivity
screen using two different checkpoint kinase inhibitors LY2606368 and AZD7762 in a panel
of 49 HNSCC cell lines. 9 out of a panel of 49 HNSCC cell lines (20%) were found out to be
acutely sensitive to Chk inhibitor monotherapy as assessed by MTT based cell
proliferation/viability assay. The IC50 value of LY2606368 and AZD7762 for the Chk inhibitor
sensitive (hereafter sensitive) cell lines, as evaluated by MTT assay ranged from 1 to 4
nmol/L and 20-80 nmol/L, respectively, (Figure 44). On the other hand, cell lines that were
deemed resistant to Chk inhibitors in the screen exhibited IC50 value greater than 5 nmol/L
for LY2606368 and greater than 100 nmol/L for AZD7762.
To investigate whether the acute sensitivity to Chk inhibition in a panel of HNSCC cell
lines, evident through the MTT screen, was an outcome of decreased cell survival, we
assessed the colony formation ability of four sensitive and three resistant cells in the
presence of various concentration of LY2606368. The cells were exposed to the drug
continuously for 48 hrs and washed out, and colonies were allowed to form for 12 days.
The clonogenic LY2606368 IC50 value for the sensitive 183, UMSCC1, UMSCC4 and
MDA1386 cells was between 3.0 to 3.4 nmol/L, 2.8 to 3.4 nmol/L, 2.5 to 3.1 nmol/L, and
1.6 to 2.0 nmol/L, respectively, (Figure 45). On the other hand, the resistant HN31, FADU
and Cal27 exhibited an IC50 value between 13.1 to 15.5 nmol/L, 16.7 to 22.3 nmol/L, and
26.4 to 33.5 nmol/L, respectively.
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Figure 42: Acute sensitivity to Chk inhibitor (AZD7762) in a subset of HNSCC cell lines
HN5, Cal27, SCC61 were seeded at a density of 300-600 cells/well in a 6 well plate in
triplicates. Next days, cells were treated with AZD7762 at a single dose of 100 nM (0.1 %
DMSO) for 48hrs. At 48hrs time point, media containing the drug was removed and cells
were washed with PBS two times, and fresh media was supplied. Colonies were allowed to
form for 10-12 days, after which they were fixed in methanol and stained with crystal
violet. Experiment was repeated at least twice. Representative images of the colonies
under each treatment for each cell line are shown.
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Figure 43: Acute sensitivity to Chk inhibitor (LY2606368) in a subset of HNSCC cell lines
183 and FADU cells were seeded at a density of 800-1000 cells/well in a 6 well plate in
triplicates. Next days, cells were treated with LY2606368 at a single dose of 3nM (0.1 %
DMSO) for 48hrs. At 48hrs time point, media containing the drug was removed and cells
were washed with PBS two times, and fresh media was supplied. Colonies were allowed to
form for 10-12 days, after which they were fixed in methanol and stained with crystal
violet. Experiment was repeated three times. Representative images of the colonies under
each treatment for each cell line are shown.
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Figure 44: IC50 values of AZD7762 and LY2606368 in 49 HNSCC cell lines
HNSCC cells seeded in 96 well plate were treated with LY2606368 or AZD7762 at various
concentrations (diluted in 0.1% DMSO) in quadruplicates for 2 days. At 48hrs, media
containing the drug was aspirated and cells were washed with PBS and supplied with fresh
media. At day 4 or 5, cells were incubated with MTT reagent for 2hrs. After removing MTT
reagent, 100 % DMSO was added to each well, and optical density values were obtained on
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micro plate reader. Cell line IC50 value for each drug was determined by plotting the
absorbance/cell viability vs concentration graph. Cell lines exhibiting AZD7762 IC 50 value >
200 nM or LY2606368 IC50 value > 40 nM are plotted in red bars. Dashed line on the graphs
denotes a cutoff value for sensitivity to AZD7762 and LY2606368. Cell lines with IC50 values
below the dashed line were deemed sensitive to both Chk inhibitors, while those with IC 50
values above the dashed lines were deemed resistant to the inhibitors.

Figure 45: A subset of HNSCC cell lines is hypersensitive to Chk1 inhibition
Sensitive and resistant cells seeded for clonogenic assays were exposed to LY2606368 at
various concentrations for 48 hrs after which cells were washed two times with PBS and
supplied with fresh media. Colonies were allowed to form for 12-14 days, after which they
were stained, and counted. Surviving colonies under the treatments were normalized to
control and IC50 values were determined by plotting surviving fraction versus log
LY2606368 concentration from three independent experiments.
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Sub Aim 1.1.1: To determine the effect of siRNA knockdown of Chk1 and Chk2 kinase in
sensitive and resistant cells
Although these two drugs have been reported to be highly specific for their intended
targets, it is difficult to ensure a 100% specificity for any small molecule inhibitor. With this
mind, we considered a possibility that drug-related off target effects may be contributing
towards this acute sensitivity phenotype. To test this, we performed a siRNA knockdown of
Chk1 and Chk2 kinases in sensitive UMSCC1 and 183 cells and found that Chk1, but not
Chk2 knockdown, resulted in a significant reduction in cell proliferation compared to the
scramble siRNA, as assessed by MTT assay (p<0.001) (Figure 46). Chk1 and Chk2 target
knockdowns were confirmed by western blot (Figure 46). In stark contrast, the siRNA
knockdown of Chk1 or Chk2 in the resistant HN31 and FADU cells led to minimal or no
reduction in the cell proliferation over scramble siRNA (p>0.05) (Figure 47). The Chk1 and
Chk2 target knockdowns were confirmed by western blot as shown in (Figure 47). From
these results, we inferred that Chk1, but not Chk2, mediates the cell viability in the
sensitive cells.
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Figure 46: Chk1, but not Chk2 mediates cell viability in sensitive cells
UMSCC1, 183 cells were electroporated with scramble siRNA or siRNA targeting Chk1 or
Chk2. Immediately after electroporation, cells under each siRNA condition were seeded at
equal density in quadruplicates in 96 well-plates. Next day, a MTT based colorimetric assay
was performed to obtain baseline OD readings. 5 days post electroporation, OD readings
were determined again. The Net OD or the difference between the day five and day zero
reading under each condition was plotted as shown. Western blot was performed to
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confirm siRNA knockdown of Chk1 and Chk2 in all four cell lines using their cell lysates
collected at 30 hrs post electroporation. ‡, Significantly lower than scramble siRNA, using
two tailed Student t test. n.s, differences not statistically significant (p>0.05).
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Figure 47: Chk1 or Chk2 knockdown has not effect on cell viability in resistant cells
FADU and HN31 (resistant) cells were electroporated with scramble siRNA or siRNA
targeting Chk1 or Chk2. Immediately after electroporation, cells under each siRNA
condition were seeded at equal density in quadruplicates in 96 well-plates. Next day, a
MTT based colorimetric assay was performed to obtain baseline OD readings. 5 days post
electroporation, OD readings were determined again. The Net OD or the difference
between the day five and day zero reading under each condition was plotted as shown.
Western blot was performed to confirm siRNA knockdown of Chk1 and Chk2 in all four cell
lines using their cell lysates collected at 30 hrs post electroporation. Experiments were
repeated three times. ‡, Significantly lower than scramble siRNA, using two tailed Student t
test. n.s, differences not statistically significant (p>0.05).
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Sub Aim 1.1.2: To investigate if higher doses of LY2606368 are required to inhibit Chk1
kinase activity in the resistant cells
The degree of inhibition of Chk1 kinase activity at a given inhibitor dose may vary
across HNSCC cells, and could result in a differential phenotype. We questioned if the
relative resistance to Chk1 inhibitor in the remaining large panel of HNSCC cell lines was
due to the requirement of higher dose thresholds for inhibiting Chk1 kinase activity. To
investigate this, a pair of sensitive (183 and UMSCC1) and resistant (HN31 and FADU) cells
were exposed to UV irradiation (70 mJ/m2), a known activator of ATR-Chk1 pathway, and
the Chk inhibitor dose required to abolish the Chk1 kinase activity in these cell lines was
examined. No detectable levels of pChk1 (S296), a surrogate measure of Chk1 kinase
activity, was evident on western blot for both sensitive and resistant cells under baseline or
control condition (Figure 48). This is probably because the Chk1 kinase activity in these
cells, under basal condition, is very low and below the detection limit of this assay.
However, as expected, with UV irradiation, a robust increase in phospho Chk1 (S296) levels
was found in both sensitive and resistant cells. Cotreatment with LY2606368 at doses
corresponding to the IC50 or IC90 values for sensitive cells not only prevented the
accumulation of phospho Chk1 (S296) levels in the sensitive, but also in the resistant cells.
These results suggested that Chk1 kinase activity is inhibited in sensitive as well as resistant
cells at equimolar doses of LY2606368.
For all subsequent experiments, we chose a LY2606368 dose of 3 nmol/L, which is
based on the mean IC50 value of the drug for sensitive cells. In summary, the above results
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show that Chk1 kinase is critical for cell viability in a significant subset of HNSCC cells, and
that targeted inhibition Chk1 kinase alone leads to marked reduction in the colony forming
ability of these cells, while in Chk1 inhibitor resistant cells, the inhibition of Chk1 activity
alone is not sufficient to do so. This suggests that other alterations within sensitive HNSCC
cells make them susceptible to Chk1 inhibition.
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Figure 48: Equimolar doses of LY2606368 inhibits Chk1 activity in sensitive and resistant
cells
UMSCC1, 183, HN31 and FADU cells were pretreated with DMSO control or LY2606368 at 3
nM, 6 nM or 15 nM for 2 hrs. At 2 hrs, media was removed. A batch of LY2606368
pretreated cells were then exposed to UV irradiation (75 mJ/m2) and immediately supplied
with media containing LY2606368 at the same dose. At the same time, a batch of
untreated DMSO control cells were irradiated with UV – 75 mJ/m2 alone and supplied with
fresh media. After 1.5 hrs post UV exposure, cell lysates under each treatment condition
were collected and western blot was performed to probe for pChk1 (S296) levels.
Experiment was repeated at least twice. β-actin was used as loading control.
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Aim 1.2: To determine the effects of Chk inhibition on the cell cycle profile of
sensitive and resistant HNSCC cells
5.3 Chk1 inhibition evokes perturbation in S phase progression and subsequent death in
sensitive cells
Given that Chk1 kinase has a central role in the regulation of the cell cycle, especially
as an enforcer of intra-S and G2-M checkpoints, we questioned whether the Chk1
inhibition may lead to an alteration in the cell cycle profile of sensitive (UMSCC1 and 183)
and resistant (HN31 and HN4) cells. To address this question, we performed two
complementary assays. Firstly, a very peculiar alteration in the cell cycle profile of sensitive
cells was evident upon treatment with Chk inhibitors as assessed by PI based cell cycle
analysis using flow cytometry. At 12 and 24hrs time points, compared to no treatment, we
observed a strong accumulation in the early S phase part of the cell cycle, upon treatment
with LY2606368 (3 nmol/L) or AZD7762 (100 nmol/L) in the sensitive cells (p<0.001) (Figure
49). Interestingly, at the 24hr time point, there was a drop in the S phase accumulation of
sensitive cells, but an increase in the subG1 population was detected (Figure 50). On the
contrary, no such early S phase accumulation or alteration in the cell cycle profile was
evident in the resistant cells upon treatment with the chk inhibitor (Figure 51).
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Figure 49: Cell cycle alteration in response to single agent Chk1 inhibition in sensitive and
resistant cells
146

147

Figure 50: Chk1 inhibition leads to S phase accumulation in sensitive cells
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Figure 51: Chk1 inhibition does not lead to S phase accumulation in resistant cells
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Figures 49 to 51, UMSCC1, 183 (sensitive), HN4 and HN31 (resistant) cells were seeded at
200- 300K cells in 6 cm dish. Next day, cells were either treated with DMSO control or
treated with AZD7762 (100 nM) or LY2606368 (3nM). At the indicated time points, cells
were collected, fixed overnight at 40C in 70% ethanol. After collection of all the samples,
they were processed together, stained with propidium iodide solution and cell cycle
analysis was performed on flow cytometry instrument. Figure 50 and 51, the mean fraction
of cells in each cell cycle phase was calculated from three independent experiments and
plotted. The fraction of cells in S phase for all four cell lines are plotted in a different graph.
†, ‡ significantly higher percentage compared to control untreated cells, using two tailed
Student t test.
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Because IC50 doses of AZD7762 and LY260636 for sensitive cells were used for this
assay, we wondered whether this phenotypic occurrence could be elicited in the resistant
cells at an equitoxic dose (i.e. close to IC50 for resistant cells) of Chk inhibitor. We found
that treatment of resistant cells (HN31 and FADU) with a corresponding equitoxic dose of
LY2606368 (20 nmol/L and 30 nmol/L, respectively), resulted in G2/M arrest, instead of
early S phase arrest (Figure 52). This distinct cell cycle alteration observed in these cells is
likely an outcome of drug-related off-target effect, since a 6 to 10 fold higher dose of
LY2606368 than required for Chk1 inhibition was used.
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Figure 52: Treatment with higher doses of LY2606368 induces G2/M accumulation in
resistant cells
HN31 and FADU (resistant) cells were seeded at density 200-300K cells/6 cm dish. Next
day, HN31 and FADU cells were exposed to LY2606368 at dose of 20 nmol/L and 30
nmol/L, respectively. At the indicated time points, cells were trypsinized, fixed overnight in
70% ethanol. After collection of all the samples, they were stained with propidium iodide
solution and cell cycle analysis was performed on flow cytometry instrument. The mean
fraction of cells in each cell cycle phase was calculated from three independent
experiments and plotted. Representative cell cycle images under each treatment condition
at given time points are shown.
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Next, we performed BrdU incorporation assay to monitor cell cycle progression in the
presence of Chk1 inhibitor in sensitive UMSCC1 cells. At 3, 6 and 9 hrs time points,
compared to untreated cells, we found that Chk1 inhibition led to a moderate increase in
the percentage of BrdU positive cells (con vs Chk1 inhibitor, 13% vs 16.6%, 15.6% vs 18%,
14.6% vs 17.8%, respectively) within the gated population (Figure 53). However, a
significant increase in the percentage of BrdU positive cells, compared to control cells, was
evident at 12 and 15 hrs time points (p<0.0001) with the Chk1 inhibition. These results
suggested that fraction of cells undergoing DNA replication rose in response to Chk1
inhibition which is consistent with our PI based cell cycle data. Although there was an
increase in the BrdU positive cells with the Chk1 inhibition, compared to control cells, the
mean intensity of BrdU within the gated population was found to be significantly lower
after Chk1 inhibition at 6,9,12, and 15 hrs time points (p<0.01) (Figure 53). These results
suggested that there was perturbation in the progression of DNA synthesis after Chk1
inhibition.
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Figure 53: Chk1 inhibition leads to increased S phase fraction of sensitive cells
UMSCC1 cells were treated with DMSO or LY2606368 (3nM). At indicated time points, cells
under each treatment condition were pulse labelled with BrdU 10 μM for 40 min and
immediately harvested after that. Cells were then processed as per the manual instructions
and analyzed on Flow cytometry instrument on FITC vs PI channel. A batch of untreated
cells not subjected to BrdU pulse-labelling were assessed for background signal. The gating
was kept constant for all the samples and the percentage of BrdU positive cells within the
gated population was assessed and plotted as shown in figure. The experiment was
performed at least two times. *, significantly higher percentage than the control or
untreated cells by two-tailed Student t test

Figure 54: Chk1 inhibition leads to perturbation in the progression of DNA replication
The mean intensity of BrdU within the gated population was evaluated using FlowJo
software. **, significantly lower than the control or untreated cells by two-tailed Student t
test.
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Sub Aim 1.2.1: To determine phase of the cell cycle in which the sensitive HNSCC cells
undergo death in response to Chk1 inhibition
Because we had observed a concomitant increase in the subG1 population along with
a strong early S phase arrest in response to Chk1 inhibition in the sensitive cells, we
hypothesized that the sensitive cells may be undergoing death in the S phase in response
to Chk1 inhibition. To examine this possibility, we performed double thymidine block to
synchronize sensitive UMSCC1 cells in the G1 phase of cell cycle. The schema for double
thymidine block experiment is shown (Figure 55).
At the end of the double thymidine block, we performed cell cycle analysis to assess
the level of cell synchronization. Approximately 85% synchronous G1 cell population was
obtained after double thymidine block (4th bar from the bottom) (Figure 56). At 3 hrs post
release from double thymidine block, both LY2606368 treated as well as untreated
synchronized cells (5th and 7th bars from the bottom) showed a buildup in the S phase,
indicating that a fraction of synchronized cells under both conditions had already begun
DNA synthesis by 3 hrs. At 7 hrs, we detected a drop in the S phase buildup, and an
increase in the G2/M phase of the untreated synchronized cells (6th bar from the bottom),
which suggested that a fraction of the untreated synchronized cells had completed
replication and exited S phase by 7 hr time point. In contrast, a prolonged S phase buildup
in the LY2606368 treated synchronized cells was evident at this time point (8th bar from the
bottom). Importantly, this prolonged S phase buildup in LY2606368 treated synchronized
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cells was accompanied with a significant increase in the subG1 fraction over untreated
synchronized cells (p<0.0001) (Figure 57).

Figure 55: Schema for double thymidine block experiment
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Figure 56: Sensitive cells undergo death in the S phase in response to Chk1 inhibition
.
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Figure 57: Sensitive cells undergo death in the S phase in response to Chk1 inhibition
Figure 55, the schema for double thymidine block experiment is shown. UMSCC1 cells
were seeded at 150K cells/6cm dish. Next day, cells were treated with 2mM thymidine for
12 hrs (1st thymidine block) after which they were washed in PBS three times and
incubated with fresh media for 9 hrs (Release). After 9 hrs of release, the cells were again
treated with 2mM thymidine for 18 hrs (2nd thymidine block). At the end of 2nd thymidine
block, cells were washed two times with PBS, supplied with media containing DMSO or
LY2606368 (3nM). At the same time, a batch of cells not subjected to double thymidine
block were treated with DMSO or LY2606368 (3nM). At indicated time points under each
treatment condition, cells were harvested and fixed overnight in 70% ethanol. All the
samples were then stained with propidium iodide solution and cell cycle analysis was
performed on flow cytometry instrument. Experiments were repeated at least twice.
Figure 56, the cell cycle distribution obtained under each treatment condition was plotted
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as shown. Figure 57, the subG1 fraction under each treatment condition is plotted
separately in a different graph. *, significantly greater than untreated cells (post thymidine
block release) at 7hrs time point by two tailed Student t test
A similar cell cycle synchronization experiment was performed with resistant HN31
cells (Figure 55). A close to 89% synchronous G1 cell population was obtained after double
thymidine block in HN31 cells (4th bar from the bottom) (Figure 58). At 3 hrs post
thymidine block release, a majority of untreated as well LY2606368 treated synchronized
HN31 cells were detected in the S phase (approx. 86% and 91%, respectively) (5th and 7th
bars from the bottom). By 7hrs, a majority of the untreated synchronized cells exited the S
phase and a stark increase in the G2/M fraction was observed (6th bar from the bottom).
Surprisingly, a prolonged S phase buildup was detected in LY2606368 treated synchronized
cells at this time point (8th bar from the bottom). However, more importantly, no increase
in the subG1 fraction was observed in either LY2606368 treated or untreated HN31 cells
post synchronization (Figure 58).
Thymidine treatment of Chk1 depleted cells has previously been shown to induce
prolonged S phase arrest in various in-vitro tumor models [201-203] . It is likely that the S
phase accumulation seen in the resistant HN31 cells after LY2606368 treatment, post
thymidine block release, is due to the residual thymidine present after PBS washout of
these cells.
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Figure 58: Chk1 inhibition does not induce subG1 fraction in resistant cells
HN31 cells were seeded at 150K cells/6cm dish. Next day, cells were treated with 2mM
thymidine for 12 hrs (1st thymidine block) after which they were washed in PBS three times
and incubated with fresh media for 9 hrs (Release). After 9 hrs of release, the cells were
again treated with 2mM thymidine for 18 hrs (2nd thymidine block). At the end of 2nd
thymidine block, cells were washed two times with PBS, supplied with media containing
DMSO or LY2606368 (3nM). At the same time, a batch of cells not subjected to double
thymidine block were treated with DMSO or LY2606368 (3nM). At indicated time points
under each treatment condition, cells were harvested and fixed overnight in 70% ethanol.
All the samples were then stained with propidium iodide solution and cell cycle analysis
was performed on flow cytometry instrument. Experiments were repeated at least twice.
Figure 58, the cell cycle distribution obtained under each treatment condition was plotted
as shown.
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Next, we wondered if the increase in the subG1 fraction in the sensitive cells upon
Chk1 inhibition could be due to induction of apoptosis. Interestingly, only one cell line,
showed PARP cleavage post Chk1 inhibition treatment which suggests that sensitive cells
may be undergoing different modes of cell death post Chk1 inhibition (Figure 59).
Collectively, these results show that Chk1 inhibition elicits early S phase accumulation in
the sensitive, but not resistant cells. While the sensitive cells undergo death in the S phase
post Chk1 inhibition, it is likely that different cell death mechanisms may be operating in
the sensitive cells in response to Chk1 inhibition.

Figure 59: Sensitive cells maybe dying through different mechanisms in response to Chk1
inhibition
HN5, UMSCC1, 183 and HN31 cells were treated with DMSO or LY2606368 (3nM), and cell
lysates were collected at 24hrs. Western blot was performed to probe for the levels of
cleaved PARP under each treatment condition. * indicates band corresponding to cleaved
PARP. Experiment was repeated at least two times β- actin was used as loading control.
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Aim 1.3: To determine molecular signaling changes in response to Chk1
inhibition in the sensitive and resistant cells.
5.4: DNA damage and replication stress markers are selectively induced in the sensitive
cell upon Chk1 inhibition
Next, we undertook a detailed characterization of molecular responses to Chk1
inhibition in the Chk sensitive (UMSCC1 and 183) and resistant (HN31 and HN4) HNSCC
cells by immunoblotting. We observed that the sensitive cells displayed slightly higher
basal levels of pChk1 (S345) than the resistant cells and LY2606368 treatment lead to
further increase in its levels in both sensitive and resistant cells (Figure 60). To determine
which canonical upstream kinases, ATR or ATM, were responsible for the higher basal level
of pChk1 (S345) in the sensitive cells, we performed a siRNA knockdown of ATR or ATM or
both in UMSCC1 cells and then assessed the pChk1 (S345) levels 24hrs post
electroporation. The siRNA knockdown of ATR alone or a double knockdown of ATR and
ATM, led to a reduction in the pChk1 (S345) levels (Figure 61). Knockdown of ATM alone
did not have any effect on pChk1 (S345) levels. These results indicated that ATR is
responsible for higher basal levels of pChk1 (S345) in the sensitive cells. Because pChk1
(S345) site is critical for Chk1 activation, and that inhibition of Chk1 activity resulted in
decreased viability of the sensitive cells, we wondered whether inhibition of its upstream
kinase, ATR, would also lead to the same phenotype. To our surprise, we found that ATR
inhibition did not have a differential effect on the cell viability of sensitive UMSCC1 and
resistant HN31 cells (Figure 62).
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Figure 60: DNA damage and replication stress markers are selectively induced in the
sensitive cells upon Chk1 inhibition
HN31 and HN4 (resistant cells), UMSCC1 and 183 (sensitive cells) were treated with DMSO
or LY2606368 (3nM) and cell lysates were collected at 24hrs. Western blotting was
performed using these cell lysates and the levels of various cell signaling molecules under
each condition was assessed. Experiment was repeated at least two times. β- actin was
used as loading control.
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Figure 61: ATR is responsible for basal Chk1 phosphorylation at S345 site in sensitive cells
UMSCC1 cells with either mock electroporated or electroporated with scramble, siATR,
siATM or their combination. Cells were then immediately seeded for western blot and cell
lysates were collected at 24 or 48 hrs post electroporation. Western blotting was
performed to probe for the levels of ATR, ATM and pChk1 (s345) under each treatment
condition. The experiment was repeated at least two times. β- actin was used as loading
control.
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Figure 62: ATR inhibition does not have differential impact on the clonogenic survival of
sensitive and resistant cells
HN31 and UMSCC1 cells were seeded for clonogenic assay. Next day, cells were exposed to
various concentrations of ATR inhibitor ETP-46464 for 48hrs. At 48hrs, media was removed
and cell were washed two times with PBS and fed with fresh media. Colonies were allowed
to form for 10-12 days and counted. The mean colony count at various concentrations
were normalized to the control and IC50 values were generated on GraphPad Prism by
plotting fraction survival versus log ETP46464 concentration graph. Experiment was
repeated at least twice.

168

To further characterize changes in the signaling molecules under treatment
condition, we probed for the levels of gamma H2AX in sensitive and resistant cells. Higher
basal levels of gamma H2AX have been associated with sensitivity to Chk1 inhibition in
melanoma cells and inhibition of Chk1 kinase have been shown to enhance these levels
even further [197]. Here, we observed that sensitive and resistant HNSCC cells both had
comparable basal levels of gamma H2AX; however, sensitive cells displayed a marked
elevation in these levels upon Chk1 inhibition (Figure 60). On the contrary, no such
increase in the gamma H2AX levels was evident in the resistant cells.
Various cellular biological pathways are known to affect gamma H2AX levels
suggesting that gamma H2AX may not be a specific marker of DNA damage [206-208]. To
examine whether increase in the gamma H2AX levels was indeed an outcome of enhanced
DNA damage, we sought to directly observe and quantify the fraction of cells exhibiting
structural aberrations after LY2606368 treatment in the sensitive cells by performing
metaphase spread analysis (Figure 63). Consistent with the results from gamma H2AX blot,
the fraction of cells exhibiting structural aberrations including breaks and fusion were
basally similar across sensitive and resistant cells (Figure 64). Compared to no treatment, a
significantly higher fraction (%) of the cells displayed structural aberrations upon
LY2606368 treatment in the sensitive cells (p<0.0001). On the contrary, in the resistant
cells, the LY2606368 treatment did not induce significant increase in the fraction of cells
displaying structural aberrations over untreated cells (p>0.05). In addition, when we
probed for the levels of pATM (S1981), a DSBs marker, no difference in the basal phospho
ATM (S1981) levels was evident (Figure 60), however, an elevation in the phospho ATM
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(S1981) levels was evident post Chk1 inhibition in the sensitive cells, but no such elevation
was seen in the resistant cells. These results suggested that induction of severe DNA
damage including lethal DSBs post Chk1 inhibition may have contributed towards loss of
cell viability in the sensitive cells.
Another protein that was selectively induced in the sensitive cells post LY2606368
treatment was hyper phosphorylation of RPA34. RPA is a heterotrimeric protein complex
that binds, stabilizes, and protects ssDNA regions from nucleolytic cleavage [209-211]. The
phosphorylation of the middle subunit of this complex, RPA34, occurs only in the presence
of ssDNA. The hyper phosphorylation band of RPA34 together with gamma H2AX induction
is commonly associated with the presence of replication stress in cells [212]. Interestingly,
in our western blot, a strong hyper phosphorylated band of RPA34 was detected in
sensitive cells following Chk1 inhibition, while no such band was detected in the resistant
cells with or without Chk1 inhibition. These results suggested that Chk1 inhibition perhaps
led to an induction of replication stress in the sensitive cells. Induction of replication stress
has also been shown to trigger activation of p38 stress signaling pathway (SAPK pathway)
[213-215]. As an additional evidence to support replication stress induction in the sensitive
cells due to Chk1 inhibition, we probed for the levels of pHSP27 (S82), a downstream
mediator p38 stress signaling response (SAPK pathway) [215]. A striking elevation in the
pHSP27 (S82) levels following Chk1 inhibition was detected in the sensitive cells, however,
no such increase was observed in the resistant cells. Collectively, our results suggest that
inhibition of Chk1 induces replication stress and DNA damage selectively in the sensitive
cells.
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Figure 63: Chk1 inhibition induces many chromosomal breaks in sensitive, but not
resistant cells

171

Figure 64: Chk1 inhibition leads to significant increase in the fraction of sensitive cells
exhibiting chromosomal breaks and fusions
Sensitive (183, UMSCC1, UMSCC22A, HN5) and resistant (HN31, FADU) HNSCC cells in were
treated DMSO control (con) or LY2606368 for 24hrs. After 24hrs, cell were incubated with
colcemid for 25 min at 370C, and subsequently treated with hypotonic KCL for 20 min at
room temperature. After fixing the cells on slides in methanol: acetic acid (3:1) for 15 min,
the slides were air dried and stained with Giemsa. Slides were analyzed for chromosomal
aberrations that included chromosome and chromatid type breaks and fusions. A total of
35 metaphases were analyzed from each sample and the experiment was repeated three
times. Percentage of cells containing chromosomal aberrations including breaks and
fusions under each condition are plotted. Experiment was repeated three times.
Representative images of metaphase spread for UMSCC1 and HN31 cells under control or
LY2606368 treatment condition is shown. Black arrow indicates chromosomal breaks. *,
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significantly higher percentage than untreated cells by two tailed Student t test; n.s,
differences not statistically significant. Experiment performed by Dr. Asha Multani

Aim 1.4: To determine the effect of Chk1 inhibition on replicative origin
firings in sensitive and resistant cells
5.5: Chk1 inhibition lead to increase in unscheduled origin firings in the sensitive cells
The results so far suggested that Chk1 inhibition induced replication stress through
perturbation in DNA replication, may have contributed towards lethal phenotype in the
sensitive cells. So, we sought to investigate the role of Chk1 with a focus on DNA
replication. The DNA replication is very well-orchestrated process that is initiated through
temporal firings of origin across the entire genome [216]. Chk1 kinase serves to regulate S
phase progression by suppressing premature origin firings which could be deleterious for
the cells [140, 141, 143, 216]. This led us to investigate whether perturbation in DNA
synthesis was due to an aberrant increase in origin firings. To test this, we employed the
DNA fiber spread technique to assess origin firings after LY2606368 treatment in both
sensitive UMSCC1 and resistant HN31 cells. The schema for the DNA fiber spread
technique is shown.
The basal levels of origin firings were not significantly different between UMSCC1 and
HN31 cells (Figure 65 and 66). However, roughly a 2 fold increase in the origin firings over
no treatment, was detected in the UMSCC1 cells in response to Chk1 inhibition (P<0.0001).
On the other hand, no significant increase in the levels of origin firings was observed in the
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resistant cells post Chk1 inhibition (p>0.05). Furthermore, we also found that LY2606368
treatment led to short tracks of labeled DNA fibers in UMSCC1 cells which suggested of
stalling or collapse of the DNA replication fork (images panel 2 and 4 Figure 65) . In
contrast, no reduction in the labelled tracks was evident in HN31 cells post Chk1 inhibition.
These results are in agreement with our cell cycle data wherein we saw impedance of S
phase progression upon Chk1 inhibition in the sensitive, but not in resistant cells (Figure 49
and Figure 51).
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Figure 65: Experimental schema for DNA fiber spread and representative DNA fiber
spread images in sensitive and resistant cells
UMSCC1 and HN31 cells were pretreated with DMSO or LY2606368 (5 nM) for 90 min, and
then pulse-labelled serially with CldU and IdU for 30 min each. The treatment with
LY2606368 was continued throughout the experiment. CldU and IdU labelling were
incubated with specific primary antibodies, and detected by secondary green and red
antibodies, respectively

Figure 66: Chk1 inhibition leads to aberrant increase in origin firings in the sensitive cells
Greater than 400 fibers were analyzed under each condition. New origin firings were
quantified as a percent of total replication structures obtained during 1st and 2nd labeling.
Representative images are shown. *, significantly different from control or untreated cells
using one way ANOVA and Sidak’s multiple comparison test. Experiment performed and
analyzed by Dr. Raj Pandita and Dr. Durga Udaykumar.
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Conditions of prolonged replication stress have been reported to trigger a
polymerase class switching from replicative polymerase to translesion polymerase (TLS) in
order to bypass replication block or overcome fork stalling [217, 218]. PCNA
monoubiquitination is thought to be signal for this class switching [218, 219]. Interestingly,
we observed an elevation in monoubiquitinated PCNA in the UMSCC1 cells post Chk1
inhibition, which was not observed in HN31 cells (Figure 67). When we probed for the
protein expression levels of the DNA polymerase, pol eta (Pol η), we found that Chk1
inhibition lead to decreases in its level in the UMSCC1 cells (Figure 67). However, no such
decrease was evident in the resistant cells. It may be possible that impedance to
replication progression upon Chk1 inhibition in the sensitive cells could be due to
insufficient recruitment of polymerase eta because of reduction in its protein levels.
Alternatively, resistance to Chk1 inhibition could be mediated through stabilizing fork
progression through upregulation of Pol eta expression.
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Figure 67: Chk1 inhibition leads to elevation in the levels of ubiquitinated PCNA and
drop in Pol η levels
HN31 and UMSCC1 cells were treated with DMSO or LY2606368 (3nM) for 24hrs and cell
lysates were collected. Western blot was performed to probe for the levels of total and
monoubiquitinated PCNA and Pol η. β- actin was used as loading control. Experiment was
repeated at least two times.
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Sub Aim 1.4.1: To determine if LY2606368 treatment induced phenotype in sensitive cells
could be reversed through inhibition of DNA replication initiation
5.6: Cdk2, not cdk1, modulates the cellular outcomes upon Chk1 inhibition in sensitive
cells
If LY2606368 treatment induced aberrant origin firings, chromosomal breakage and
cell death in sensitive cells, we hypothesized that inhibition of initiation of DNA synthesis
should decrease the fraction of cells responding to Chk1 inhibition. It is known that the
initiation of DNA synthesis is triggered by the action of Cdks and Cdc7-Dbf4 kinase.
Although cyclin dependent kinase 2 (cdk2) is considered the key Cdk controlling DNA
replication, cdk1 can compensate when cdk2 function is lost [133]. To investigate our
hypothesis, we performed a siRNA knockdown of cdk1 or cdk2 alone or their combination
in the sensitive UMSCC1 cells, and later exposed to LY2606368 treatment. The siRNA
knockdown of cdk1 and cdk2 was confirmed by western blot as shown in Figure 68.
LY2606368 treatment of scramble or non-targeting siRNA transfected UMSCC1 cells
led to a significant reduction in the colony survival over no treatment (p<0.0001) (Figure
69). Compared to scramble or non-targeting siRNA, the cdk1 knockdown alone led to
moderate but significant reduction in the colony survival of the UMSCC1 cells (p<0.001).
The treatment of cdk1 knockdown cells with LY2606368 led to a significant reduction in the
colony survival over cdk1 knockdown alone, indicating that cdk1 knockdown does not
prevent Chk1 inhibition induced lethal phenotype (p<0.0001). The siRNA knockdown of
cdk2 alone did not lead to significant change in the colony survival of UMSCC1 cells as
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compared to scramble or non-targeting siRNA (p>0.05). Strikingly, the loss of colony
survival upon LY2606368 treatment of UMSCC1 cells was significantly reduced with the
knockdown of cdk2 (p<0.0001) and a near complete rescue from lethal phenotype was
observed. Similar to cdk1 knockdown alone, the double knockdown of cdk1 and cdk2 also
led to a significant reduction in the colony survival of UMSCC1 cells over scramble or nontargeting siRNA (p<0.001). However, a significant increase in the colony survival of
UMSCC1 cells post LY2606368 treatment was evident with the double knockdown of cdk1
and cdk2 (p<0.0001). Furthermore, the colony survival differences between LY2606368
treated and untreated double knockdown of cdk1 and cdk2 cells were found to be
statistically significant.
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Figure 68: siRNA knockdown of cdk1 and cdk2 in UMSCC1 cells
UMSCC1 cells were electroporated with scramble, siRNA targeting Cdk1, Cdk2 or their
combination and seeded for western blot and cell lysates were harvested 27hrs later.
Western blot was performed to confirm knockdown of cdk1 and cdk2 in UMSCC1 cells.
Experiment was repeated at least two times.
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Figure 69: cdk2, but not cdk1, mediates Chk1 inhibition induced lethality in sensitive cells
UMSCC1 cells were electroporated with scramble, siRNA targeting Cdk1, Cdk2 or their
combination. Immediately after electroporation, cells were counted and seeded at equal
density in 6 cm dishes in triplicates for clonogenic assay. 27 hrs post electroporation, cells
under siRNA condition were exposed to DMSO or LY2606368 (3nM) for 48hr, after which
cells were washed with PBS and media was replaced. Colonies were allowed to form for 10
days and stained with crystal violet. Colonies were then counted, normalized to scramble
untreated cells and plotted on the graph as shown. Experiment was repeated at least three
times. Representative images of colonies under each treatment are shown. *, # and **,
significantly lower than scramble or non targeting siRNA cells; ‡, significantly higher than
LY2606368 treated scramble or non targeting siRNA cells; †, significantly lower than cells
with cdk1 knockdown alone; ***, significantly lower than cdk1 and cdk2 double
knockdown cells , all using one way ANOVA and bonferroni multiple comparison test
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As additional evidence to support to our hypothesis, we used an alternative approach
to inhibit origin firings using Roscovitine which is a pan cdk inhibitor[142]. Sensitive 183
cells seeded for clonogenic assay were pre-treated with 5 μM Roscovitine for 2hrs and then
were exposed to the combination of LY2606368 (3 nmol/L, 6 nmol/L) and Roscovitine for
48hrs. As expected, the LY2606368 treatment alone at 3 nmol/L and 6 nmol/L doses led to
a significant reduction in the colony survival of 183 cells compared to control or untreated
cells (p<0.0001) (Figure 70). The Roscovitine treatment alone displayed only marginal
effect on the colony survival of 183 cells which did not reach statistical significance
(p>0.05). Strikingly, cotreatment with Roscovitine significantly improved the colony survival
of 183 cells after LY2606368 treatment at both 3 nmol/L and 6 nmol/L doses (p<0.0001).
Based on these results, we hypothesized that Chk1 inhibition may be causing an
increase in the cdk2 activity in the sensitive cells. To our surprise, we were unable detect
an increase in cdk2 activity in the UMSCC1 cells after LY2606368 treatment (Figure 71).
Because Roscovitine cotreatment rescued the sensitive cells from Chk1 inhibition-induced
colony killing, we predicted that all other phenotypic changes observed upon Chk1
inhibition in the sensitive cells could be reversed upon co-treatment with Roscovitine. We
first performed PI based cell cycle analysis in UMSCC1 and 183 cells after Chk1 inhibition
with or without Roscovitine cotreatment. A 2 fold higher dose of Roscovitine (10 μM) than
used for clonogenic assay was employed for this assay. As expected, an increase in the
early part of the S phase was detected with LY2606368 treatment alone in UMSCC1 and
183 cells. Interestingly, we observed an increase in the G2/M fraction of 183 and UMSCC1
cells with the Roscovitine treatment alone. This increase in the G2/M fraction after
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Roscovitine treatment could be due to the inhibition of cdk1, one of the targets of
Roscovitine, which is a critical regulator of the G2 checkpoint. More importantly,
cotreatment with Roscovitine prevented the Chk1 inhibition induced early S phase
accumulation in UMSCC1 and 183 cells which is consistent with our prediction (Figure 72).
Furthermore, we performed BrdU incorporation assay in UMSCC1 cells after Chk1
inhibition in presence or absence of Roscovitine cotreatment (Figure 73). As expected, an
increase in the percent BrdU positive cells was observed with the LY2606368 treatment in
the gated population at 9, 12 and 15 hrs. Cotreatment with Roscovitine led to a significant
reduction in the percent BrdU positive cells in the gated population after Chk1 inhibition at
all the time points (p<0.001). Lastly, analysis of western blot revealed that cotreatment
with Roscovitine prevented Chk1 inhibitor induced changes in the levels of signaling
molecules in the UMSCC1 cells (Figure 74).
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Figure 70: Cotreatment with Roscovitine rescues the sensitive cells from Chk1 inhibition
induced lethality
183 cells were seeded for clonogenic assay in 6 cm dishes in triplicates. Next day, cells
were pretreated with DMSO or Roscovitine 5 μM for 2hrs. After 2 hrs of Roscovitine
pretreatment, cells were exposed to Roscovitine alone or Roscovitine plus LY2606368
(3nM or 6 nM) combination treatment for 48hrs. At 48hrs, media containing the drug was
removed and cells were washed with PBS two times. Cells were then fed with fresh media
and allowed to form colonies for 10-12 days. Colonies were stained with crystal violet,
counted and normalized to control treatment and plotted in the graph. The experiment
was repeated at least three times. Representative images of colonies under each
treatment condition for 183 cells are shown. *,#, significantly greater than LY606368
treated cells at 3nM and 6 nM dose, respectively by one way ANOVA and bonferroni
multiple comparison test.
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Figure 71: Chk1 inhibition does not lead to increase in Cdk2 activity in sensitive cells
UMSCC1 cells were exposed to DMSO or LY2606368 (6 nM) treatment for 12 hrs, after
which cells were harvested, fixed in formaldehyde and permeabilized in triton X-100. After
washing twice with PBS, cells were incubated with primary antibody pcdk2 (Thr160) at
room temperature for 2 hrs. Cells were washed one time with PBS and incubated with
secondary antibody Alexa fluor 468-anti-rabbit for 1 hr. Some cells were incubated with
secondary antibody alone for background signal detection (negative control). All cells were
counter-stained with propidium iodide and then processed on flow cytometry instrument.
Experiment was repeated three times. n.s, not significantly different from control cells by
two tailed Student t test.
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Figure 72: Cotreatment with Roscovitine prevents the characteristic early phase arrest
seen after Chk1 inhibition in sensitive cells
UMSCC1 and 183 cells were seeded at 200-300K cell/6 cm dish. Next day, cells were
pretreated with DMSO or Roscovitine 10 μM for 2hrs. After 2hrs, Roscovitine pretreated
cells were exposed to Roscovitine alone or Roscovitine plus LY2606368 (3nM) for 12 hrs.
Cells were harvested at 12 hrs, fixed overnight in 70% ethanol. All the samples were
stained with propidium iodide and processed for cell cycle analysis on flow cytometer. The
experiment was repeated three times. Representative images of cell cycle profile under
each treatment are shown and fraction of cells in each cell cycle phase were quantified and
plotted.
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Figure 73: Cotreatment with Roscovitine prevents the Chk1 inhibition induced increase in
S phase fraction in sensitive cells
UMSCC1 cells were pretreated with DMSO or Roscovitine (5 μM) for 2hrs. After 2 hrs,
Roscovitine pretreated cells were exposed to Roscovitine alone or Roscovitine plus
LY2606368 (3nM). DMSO pretreated cells were left unexposed or treated with LY2606368
(3nM). At indicated time points, cells under each treatment condition were pulse labelled
with BrdU 10 μM for 40 min and immediately harvested after that. Cells were then
processed as per the manual instructions and analyzed on Flow cytometry instrument on
FITC vs PI channel. The gating was kept constant for all the samples and the percentage of
BrdU positive cells within the gated population was assessed and plotted as shown in
figure. The experiment was repeated three times. *, significantly lower than LY2606368
treated cells by one way ANOVA and bonferroni multiple comparison test.
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Figure 74: Cotreatment with Roscovitine prevents the induction of molecular signaling
changes seen after Chk1 inhibition in sensitive cells
UMSCC1 cells were pretreated with DMSO or Roscovitine (5 μM) for 2hrs. After 2hrs,
Roscovitine pretreated cells were exposed to DMSO or Roscovitine plus LY2606368 (3nM)
for 24hrs. At the same time, DMSO pretreated cells were left untreated or exposed to
LY2606368 (3nM) alone. Cell lysates were collected at 24hrs, and western blot was
performed to probe for the levels of pChk1 (S345), Chk1, H2AX (S139), RPA34. β- actin was
used as loading control. Experiment was repeated at least twice.
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Aim 1.5: To determine the effect on the clonogenic survival of resistant cells
upon combined inhibition of Wee1 and Chk1 kinases
5.7: Resistant cells can be sensitized to LY2606368 treatment by inhibition of wee1
kinase
Because inhibition of Chk1 kinase failed to cause an aberrant increase in the origin
firings in HN31 cells, we wondered if these cells were dependent on other pathways to
suppress initiation of DNA replication. Interestingly, it was previously reported that besides
Chk1, mitotic Wee1 kinase can also regulate the S phase progression through control of
origin firings [220]. This led us to hypothesize that HN31 cells may be reliant on Wee1
kinase to suppress origin firings and that inhibition of Wee1 kinase should sensitize these
cells to LY2606368 treatment. Consistent with our hypothesis, we found that addition of
Wee1 inhibitor (MK1775) indeed sensitized HN31 cells to LY2606368 treatment (Figure
75).
In order to assess if this combined inhibition of Wee1 and Chk1 kinases in HN31 cells
would elicit similar characteristic changes in the cell cycle as seen in sensitive cells upon
Chk1 inhibition alone, we performed PI based cell cycle analysis in the presence of these
two inhibitors in HN31 cells. Treatment with MK1775 or LY2606368 alone had no apparent
effect on the cell cycle profile of HN31 cells (Figure 76). However, the combinatorial
treatment with these two inhibitors led to a strong G2/M instead of an early S phase
arrest. These results suggested that MK1775 may have sensitized HN31 cells to LY2606368
treatment through a different mechanism.
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Figure 75: Inhibition of Wee1 kinase sensitizes resistant cells to Chk1 inhibitor
(LY2606368)
HN31 cells seeded for clonogenic assay were exposed to DMSO, LY2606368 (3nM), MK1775 (200nM), LY2606368 plus MK-1775 for 48 hrs. Cells were then washed with PBS for
two times and supplied with fresh media. Colonies were allowed to form for 10-12 days,
after which they were stained with crystal violet. Experiments were repeated at least
twice. Representative colony images under each treatment condition are shown.
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Figure 76: Combined inhibition of Wee1 and Chk1 kinase leads to G2/M arrest in
resistant cells
HN31 cells were treated with DMSO, LY2606368 (6 nM), MK-1775 (200 nM), LY2606368
plus MK-1775 for 48hrs. Cells were then harvested, fixed in 70% ethanol, and stained with
propidium iodide and processed for cell cycle analysis. Experiment was repeated two
times. Representative cell cycle images under each treatment are shown.
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CHAPTER 6: DISCUSSION
6.1: Acute sensitivity to Chk1 inhibition in a subset of HNSCC cells
Clinical challenges such as resistance to therapy have stymied improvement in
treatment outcomes of HNSCC patients for decades [176, 185]. This had fueled efforts to
identify new molecular targets in HNSCC which could be exploited for therapeutic
advantage. In an earlier chapter, we had shown that Chk1/2 kinases are promising
molecular targets in HNSCC and demonstrated that inhibition of this kinases improves the
cisplatin efficacy in HNSCC cells where p53 function is compromised. While several early
stage clinical trials are underway to evaluate the in-vivo efficacy of Chk1 inhibitors in
combination with genotoxic agents, recent studies have reported that inhibition of Chk1
kinase alone is deleterious in certain tumor cells [162, 197, 221].
In a small screen that was initiated to evaluate the efficacy of Chk inhibitors as
chemosensitizers in HNSCC, we serendipitously found that some HNSCC cell lines were
exquisitely sensitive to single agent Chk1 inhibitor. A follow up comprehensive screen in a
panel of 49 HNSCC cells against two different Chk inhibitors showed that roughly 20%
HNSCC cells were hypersensitive to Chk1 inhibition. To our knowledge, this is the first
report where Chk1 inhibitor activity as a single agent has been evaluated in HNSCC cell
lines. Both MTT and clonogenic assays were employed to determine the IC50 values of the
LY2606368 in a panel of sensitive and resistant cells. Interestingly, in the sensitive cells, the
IC50 values determined by these two assays came out similar. This is probably because,
firstly, for both the assays the duration of LY2606368 exposure was kept the same;
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secondly, we found that a lethal dose of LY2606368 induced rapid cytotoxicity (within 72
hrs) in the sensitive cells. These results validate the use of MTT assay for assessment of IC50
value in a drug screening assay. We found out that equimolar doses of LY2606368
completely abolished Chk1 kinase activity in both Chk sensitive and resistant cells which
indicated that survival differences between the Chk sensitive and resistant cells were not
an outcome of differential inhibition of Chk1 activity in sensitive and resistant cells. Next,
we provided evidence that Chk1, but not Chk2, is a critical target of LY2606368 that
mediates survival in Chk sensitive UMSCC1 and 183 cells. In addition, our results show that
Chk1 may be dispensable for a large majority of HNSCC cells because despite achieving
close to 90% Chk1 knockdown efficiency in the resistant cells, there was no change in the
cell proliferation or viability.

6.2: Chk1 inhibition and cell cycle changes
Analysis of cell cycle revealed a striking and peculiar alteration in the cell cycle prolife
of sensitive UMSCC1 and 183 cells upon chk1 inhibition. We observed an early S phase
arrest in the sensitive cells upon treatment with Chk1 inhibitors which indicated that Chk1
was critical to ensure unimpeded S phase progression in these cells. No such alteration was
evident in the cell cycle profile of resistant cells upon Chk1 inhibition. However, treatment
with an equitoxic IC50 dose of LY2606368 elicited G2/M, instead of S phase arrest in the
resistant cells. Because this phenotype required a dose of LY2606368 that was several fold
higher than the dose required for Chk1 inhibition, we infer that this is could be an outcome
of drug related non-specific (off-target) effects. Replication assessment using BrdU
incorporation showed marked increase in the percentage of BrdU positive cells in the
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gated S phase population over untreated cells. It is plausible that this spike in the BrdU
positive cells in the early S phase upon Chk1 inhibition could be largely be due to an
aberrant increase in the initiation of DNA replication as reported by one research group
[138]. However, inhibition of Chk1 was also found to induce DNA damage in the tumor
cells, and therefore, the repair processes initiated by the cells on account of DNA damage
due to Chk1 inhibition may also incorporate BrdU and this contribution towards increased
BrdU positivity cannot be easily ruled out.
Despite a stark increase in the percent BrdU positive UMSCC1 cells upon Chk1
inhibition at later time points (Chk1 inhibition vs Con, 20.8 vs 14.2 (12hrs) and 24.3 vs 17
(15hrs)), the mean intensity of BrdU, reflecting BrdU uptake, did not increase at these time
points. Instead, a significant drop in the BrdU mean intensity was found. These results
suggested that BrdU uptake reflecting active progression of the DNA synthesis was
perturbed upon Chk1 inhibition. These results are consistent with PI based cell cycle data
of UMSCC1 cells where persistent accumulation in the early S phase part of the cell cycle
was observed following Chk1 inhibition.
6.2.1: Chk1 inhibition and S phase death
UMSCC1 cells released after cell cycle synchronization arrested in the S phase and
showed a concomitant increase in subG1 fraction following Chk1 inhibition which indicated
these cells were dying in the S phase following LY2606368 treatment. A similar S phase
arrest following cell cycle synchronization was observed in the resistant HN31 cells on
exposure to LY2606368 treatment, however, no increase in subG1 fraction was observed.
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The increase in the S phase could be attributed to the combined effect of Chk1 inhibition
and residual thymidine present in these cells after thymidine washout. With the exception
of one cell line HN5, we were unable to detect evidence of apoptosis in the sensitive cells
following Chk1 inhibition. The functional loss of ATR or Chk1 has been shown to commit
the cancer cells to distinct cells fates such as premature chromatin condensation, and
mitotic catastrophe [222, 223]. A recent study investigating the mechanism of cell death
under conditions of replication stress showed that Chk1 depleted cancer cells underwent
premature mitosis through S phase slippage [224]. This S to M slippage was shown to be
due to inappropriate activation of Aurora Kinase B. Despite strong S phase arrest observed
in the sensitive cells following Chk1 inhibition, we were able to obtain metaphase spreads
of their chromosomes. It may be possible that sensitive cells that did not show evidence of
apoptosis upon Chk1 inhibition may have slipped from S phase and undergone premature
mitosis.

6.3: Chk1 inhibition and molecular signaling changes
Assessment of molecular responses to Chk1 inhibition revealed that pChk1 (S345)
levels were basally higher in the sensitive as compared to resistant cells. While the
knockdown experiments revealed that canonical upstream target ATR was responsible for
Chk1 phosphorylation on S345 site in the sensitive UMSCC1 cells, these cells did not display
hypersensitivity to ATR inhibition. These results suggested that loss of S345
phosphorylation had no impact on the activity of Chk1 kinase. Intriguingly, ATR/ATM
independent regulation of Chk1 activity, for e.g. by claspin, has been described in the S
phase under replication stress conditions [225]. Furthermore, this ATR/ATM independent
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regulation of Chk1 activity was found not to correlate with the pChk1 (S345) levels. We
speculate that ATR/ATM independent mechanisms of Chk1 activity regulation could be at
play in the sensitive cells.
Besides pChk1 (S345), we also detected elevation in gamma H2AX, RPA34 hyper
phosphorylation, pATM (S1981) and pHSP27 (S82) levels upon LY2606368 treatment in the
sensitive cells. The metaphase spread analysis of sensitive cells showed massive
chromosomal breakage upon LY2606368 treatment and thus provided compelling evidence
that elevation in gamma H2AX levels was due to the induction of DNA damage upon
LY2606368 treatment. Hyper phosphorylation of RPA34 is believed to be a definitive
indicator of the presence of ssDNA in the nucleus, and is commonly associated with
replication stress. Studies conducted elsewhere have reported that tumor cells upon
exposure to the agents that cause DNA lesions or disruptions in DNA precursor supply are
dependent on Chk1 to limit the induction of replication stress [201-203]. Depletion of Chk1
under these conditions induced severe replication stress in the tumor cells and led to RPA
hyper phosphorylation. Strikingly, we found that Chk1 inhibition alone led to RPA hyper
phosphorylation in the sensitive HNSCC cells which suggests that these cells may be
chronically under replication stress and thus overly dependent on Chk1 to prevent
exacerbation of replication stress in these cells. Severe induction of replication stress may
result in the collapse of stalled replication forks and ultimately cause DSBs [140, 141].
Indeed, the LY2606368 treatment or Chk1 inhibition was found to elevate pATM (S1981)
levels, a marker of DSBs, in the sensitive cells.
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6.4: Chk1 inhibition and origin firings
Suppression of unscheduled origin firings to prevent catastrophic occurrences is one
of the chief functions of Chk1 in an unperturbed cell cycle. In our study, we found out that
sensitive UMSCC1 cells showed a significant increase in origin firings upon Chk1 inhibition.
The initiation of origin firings takes place through the action of Cdks, particularly cdk1 or
cdk2, that lie downstream of the ATR-Chk1 pathway. This suggested that increased origin
firings upon Chk1 inhibition may be an outcome of increased activation of these cdks as
reported by some research groups [133, 138, 142]. To our surprise, we were unable to
detect enhancement of either cdk2 activity in our cells upon Chk1 inhibition. However, we
observed that the knockdown of cdk2, but not cdk1, rescued the lethal phenotype seen
after Chk1 inhibition in the sensitive cells. Similarly, cotreatment with Roscovitine, a pan
cdk inhibitor, protected the sensitive cells from Chk1 inhibition induced killing. The above
results suggested that cellular outcomes upon Chk1 inhibition are mediated by cdk2 but
these outcomes are not strictly a result of increased cdk2 activity.
Contrary to the sensitive UMSCC1 cells, no significant increase in the origin firings
was observed in the resistant HN31 cells. These results suggested that resistant cells may
have compensatory pathways to prevent unscheduled origin firings after loss of Chk1
function. Another important kinase that operates to maintain genomic integrity in the S
phase through regulation of origin firings is Wee1 kinase [133]. Interestingly, we found that
loss of Wee1 kinase activity rendered the resistant HN31 cells sensitive to the Chk1
inhibition. However, the combined inhibition of Chk1 and Wee1 kinases evoked an
altogether different alteration in the cell cycle profile of HN31 resistant cells. Unlike early S
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phase accumulation seen in the sensitive cells upon Chk1 inhibition, these resistant cells
arrested in the G2/M phase after combined inhibition of Wee1 and Chk1 kinase. This
suggested that Wee1 kinase inhibition may have sensitized resistant cells to Chk1 inhibition
through a different mechanism.
Based on the results of our study, we propose a following model for the mechanism
of sensitivity to Chk1 inhibition in HNSCC cells. In the S phase, under unperturbed
conditions, Chk1 kinase suppresses premature initiation of replication origin firings thereby
limiting the helicase activity of unwinding the DNA. As a result, very low levels of ssDNA are
generated and the DNA synthesis progresses normally (Figure 77). Inhibition of Chk1 kinase
in the sensitive cells leads to aberrant firing of replication origins, which is followed by
uncoupling of polymerase-helicase complex due to increases in helicase unwinding activity
(Figure 78). This leads to massive accumulation of ssDNA, which serves as a signal for cell
cycle arrest and cell death. Knockdown of cdk2 or Roscovitine co-treatment in the sensitive
cells inhibits aberrant firing of replication origins upon Chk1 inhibition and limits the
helicase unwinding activity (Figure 79). As a result, the levels of ssDNA are maintained at
low levels, and the normal progression of DNA synthesis is maintained. In the resistant
cells, we hypothesize that Chk1 inhibition triggers a polymerase class switching wherein
polymerase eta is recruited onto the DNA template, which then limits the unwinding action
of the helicases (Figure 80). As a result, low levels of ssDNA are generated and normal
progression of DNA synthesis is maintained.
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Figure 77: Model for DNA replication under unperturbed conditions

Figure 78: Model for DNA replication upon Chk1 inhibition in sensitive cells
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Figure 79: Model for DNA replication upon cdk2 knockdown or Roscovitine cotreatment
in sensitive cells
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Figure 80: Model for DNA replication upon Chk1 inhibition in resistant cells
Figure 77, In the S phase under unperturbed conditions, Chk1 suppresses premature
initiation of origin firings thereby limiting the helicase unwinding of the DNA. As a result,
very low level of ssDNA is generated and DNA synthesis progresses normally. Figure 78,
Chk1 inhibition lead to aberrant initiation of replication origins and triggers uncoupling of
polymerase-helicase complex which results in high level of ssDNA accumulation.
Accumulation of ssDNA then serves as a signal for cell cycle arrest and cell death. Figure
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79, cdk2 knockdown or Roscovitine cotreatment prevents origin firings and uncoupling of
the polymerase-helicase complex. As a result, low level of ssDNA is generated and DNA
synthesis proceeds normally. Figure 80, Inhibition of chk1 kinase triggers a polymerase
class switching in the resistant cells and leads to the recruitment of pol η onto the DNA
template. Pol η prevents the accumulation of ssDNA by limiting the unwinding action of
the helicase and maintains the normal progression of DNA synthesis.

6.5: Study limitations and conclusions
Although we have clearly distinguished the cellular responses upon Chk1 inhibition in
sensitive and resistant HNSCC cells, the cellular factors that predispose certain HNSCC cells
hypersensitive to Chk1 inhibition have remained elusive. Elevated levels of gamma H2AX
have been associated with Chk1 inhibitor sensitivity by a study conducted elsewhere [197].
Our results indicate that this may not be true for all cancers because despite showing
elevated basal levels of gamma H2AX we found out that certain HNSCC cells were resistant
to Chk1 inhibition. Besides gamma H2AX, overexpression of certain oncogenes, for e.g. cMyc and N-Myc, that induce replication stress or defects in specific DNA repair pathway,
for e.g. Fanconi Anemia pathway, were shown to impart hypersensitivity to Chk1 inhibition
in cancer cells [162, 163]. We argue that sensitivity to Chk1 inhibition in HNSCC cells is not
likely due to the defect or alteration in a single gene. This is because in a previously
performed integrated genomic analysis of HNSCC patient tumors by us, we detected
multiple alterations in distinct cellular pathways that promote HNSCC [41]. Furthermore,
alterations in multiple genes in many of these deregulated cellular pathways were also
found. Thus, a single genetic alteration is unlikely to be responsible for this exquisite
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sensitivity to Chk1 inhibition in a subset of HNSCC cells. While it has proven difficult to
identify cellular factors rendering sensitivity or resistance to Chk1 inhibition in HNSCC using
genomics, a systems biology approach using an unbiased genomic shRNA screen in HNSCC
cells may be helpful to answer this important question.
In summary, Chk1 inhibitors have been shown to be efficacious as radio and chemosensitizers in a variety of cancer cells of diverse tumor origins. Currently, a number of
phase1/2 clinical trials are underway to evaluate its clinical safety and efficacy. More
recently, reports of single agent activity in various cancer cells have kindled surprise and
renewed interest to evaluate Chk1 inhibitors as monotherapy. In this study, using a large
panel of HNSCC cell lines, we have distinguished cellular responses to Chk1 inhibitor in
sensitive and resistant HNSCC cells. A clinical trial of single Chk1 inhibition in refractory
HNSCC patients has shown a similar response rate (roughly 20%) to this treatment (D. Hong
personal communication). It would therefore be ideal to identify a biomarker in patient
specimens that could signal likelihood of response to Chk1 inhibition. To get closer to this
type of precision medicine biomarker based treatment selection further understanding of
the mechanisms underlying Chk1 inhibitor sensitivity and/or resistance are needed. Based
on the results of current investigation, we propose that RPA34 hyper phosphorylation,
gamma H2AX, pATM, pHSP27 may serve as potential pharmacodynamic markers of chk1
inhibitor efficacy in HNSCC in-vitro and in-vivo preclinical studies.
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